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ABSTRACT
MCL-1, an anti-apoptotic BCL-2 family member that is essential for the survival
of multiple cell lineages, is also among the most highly amplified genes in cancer.
Although MCL-1 is known to oppose cell death, precisely how it functions to promote
survival of normal and malignant cells is poorly understood. Here, I report that different
forms of MCL-1 reside in distinct mitochondrial locations and exhibit separable
functions. On the outer mitochondrial membrane, a MCL-1 isoform acts like other antiapoptotic BCL-2 molecules to antagonize apoptosis, whereas an amino-terminally
truncated isoform of MCL-1 that is imported into the mitochondrial matrix is necessary
to facilitate normal mitochondrial fusion, ATP production, membrane potential,
respiration, cristae ultrastructure, and maintenance of oligomeric ATP synthase. My
results provide insight into how MCL-1's surprisingly diverse salutary functions may
control the survival of both normal and cancer cells.

v

TABLE OF CONTENTS
CHAPTER 1. INTRODUCTION .....................................................................................1
The BCL-2 Family Proteins and Apoptosis .....................................................................1
Anti-apoptotic MCL-1 .....................................................................................................4
MCL-1 Anti-apoptotic Function ..................................................................................4
MCL-1 and Cell Survival.............................................................................................5
MCL-1 Regulation ...........................................................................................................7
MCL-1 and Cancer ..........................................................................................................7
Dynamic Structure of Mitochondria ................................................................................8
Internal Structure of Mitochondria ..............................................................................8
Regulators of Fusion and Fission ...............................................................................11
Biological Functions ..................................................................................................11
The BCL-2 Family and Dynamics .............................................................................12
Supermolecular Protein Complexes in the Inner Mitochondrial Membrane .................13
Respiratory Supercomplexes .....................................................................................13
F1F0-ATP Synthase Dimers and Oligomers ...............................................................15
CHAPTER 2. MATERIALS AND EXPERIMENTAL PROCEDURES ...................16
Cells and Cell Culture ....................................................................................................16
Plasmids, Expression Constructs, and Generation of Mutants ......................................16
Ecotropic Retroviral Production and Cell Transduction................................................17
Western Blotting, Co-immunoprecipitation, and Antibodies ........................................17
Cell Death Experiments .................................................................................................17
RNAi Experiments .........................................................................................................18
Measurement of Superoxide Anion ...............................................................................18
Isolation and Purification of Mouse Liver Mitochondria ..............................................18
Subcellular Fractionation and Isolation of Heavy Membrane from Cells .....................18
Proteolysis of Heavy Membrane Fraction .....................................................................19
Oxygen Consumption ....................................................................................................19
Alkali Wash ...................................................................................................................19
Mitochondria Subfractionation ......................................................................................19
Cellular ATP ..................................................................................................................19
Mitochondrial Fusion Assay and Image Analysis .........................................................20
Analysis of Mitochondrial Morphology and Shape .......................................................20
Mitochondrial DNA Isolation and Quantification .........................................................20
Mitochondrial Membrane Potential and Image Analysis ..............................................21
Transmission Electron Microscopy ...............................................................................21
Immuno-electron Microscopy........................................................................................21
Immunofluorescence ......................................................................................................22
Enzymatic Activity of Electron Transport Chain Components .....................................22
Isolation of Respiratory Complexes and Supercomplexes ............................................22
Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) ....................................23
-Phosphatase Treatment ...............................................................................................23
Edman Sequencing of MCL-1 .......................................................................................23

vi

CHAPTER 3. RESULTS .................................................................................................24
Mcl-1-deletion Results in Mitochondrial Morphology Defects .....................................24
MCL-1 Localizes to Two Distinct Mitochondrial Sub-compartments ..........................24
MCL-1 Possesses a Mitochondrial Targeting Sequence ...............................................34
Inhibition of Cell Death Requires Outer Membrane-localized MCL-1 .........................34
MCL-1 Matrix-localized MCL-1 Is Required for Normal IMM Structure and
Efficient Mitochondrial Fusion ......................................................................................41
Normal Mitochondrial Bioenergetics Requires Matrix-localized MCL-1 ....................41
MCL-1 Is Required for Assembly of F1F0-ATP Synthase Oligomers .........................47
CHAPTER 4. DISCUSSION ..........................................................................................53
MCL-1 in Normal Cells .................................................................................................53
MCL-1 in Embryonic Development ..........................................................................53
MCL-1 in Hematopoiesis ...........................................................................................54
MCL-1 in the Brain ....................................................................................................56
Role of MCL-1 in Cancer and Cancer Therapy .............................................................56
Cancer Stem Cells and Differentiation Therapy ........................................................57
BCL-2 Family Inhibitors............................................................................................58
Post-translational Regulation of MCL-1........................................................................58
Regulation of Mitochondrial Function by MCL-1 ........................................................60
MCL-1 Modulates Inner Membrane Structure, Dynamics, and Function .....................60
Concluding Remarks......................................................................................................64
LIST OF REFERENCES ................................................................................................65
VITA .................................................................................................................................81

vii

LIST OF FIGURES
Figure 1.1. The BCL-2 Family ..........................................................................................2
Figure 1.2. BCL-2 Family Mediated Apoptosis ................................................................3
Figure 1.3. Apoptotic Checkpoints during Hematopoiesis ...............................................6
Figure 1.4. Mitochondrial Dynamics ................................................................................9
Figure 1.5. Mitochondrial Morphology.............................................................................9
Figure 1.6. Mitochondrial Ultrastructure ........................................................................10
Figure 1.7. Oxidative Phosphorylation............................................................................14
Figure 1.8. Respiratory Supercomplexes ........................................................................14
Figure 3.1. Inducible Mcl-1-deletion in MEFs Does Not Affect the Cell Viability........25
Figure 3.2. Inducible Mcl-1-deletion in MEFS Results in Mitochondrial
Morphology Defects. ...................................................................................26
Figure 3.3. Mcl-1-deletion Induces Mitochondrial Abnormalities..................................28
Figure 3.4. Origin of MCL-1 Protein Species. ................................................................29
Figure 3.5. MCL-1 Resides in Different Sub-mitochondrial Localizations. ...................31
Figure 3.6. MCL-1 Is Localized to Both the Outer and Inner Mitochondrial
Membranes. ..................................................................................................32
Figure 3.7. MCL-1 Undergoes TIM/TOM Mitochondrial Import. .................................33
Figure 3.8. Both the Amino (N)- and Carboxy (C)-termini Are Required for Proper
Mitochondrial Localization of MCL-1.........................................................35
Figure 3.9. MCL-1 Mutants Restrict Mitochondrial Localization. .................................37
Figure 3.10. Anti-apoptotic Activity of MCL-1 Requires Localization to the Outer
Mitochondrial Membrane.............................................................................39
Figure 3.11. Lacking Matrix-localized MCL-1 Results in Mitochondrial IMM
Structure and Fusion Defects. ......................................................................42
Figure 3.12. Human MCL-1 Rescues Mitochondrial Fusion Defect. ...............................44

viii

Figure 3.13. Matrix-localized MCL-1 Is Required for Efficient Bioenergetics and
Proliferation. ................................................................................................45
Figure 3.14. Cells Deficient in Matrix-localized MCL-1 Have Defects in Oxygen
Consumption. ...............................................................................................48
Figure 3.15. MCL-1 Is Required for Assembly of Supercomplexes.................................50
Figure 4.1. Possible MCL-1 Functions in Normal Homeostasis.....................................55
Figure 4.2. Classical Anti-apoptotic MCL-1 ...................................................................61
Figure 4.3. MCL-1’s Potential Functions Inside Mitochondria ......................................63

ix

LIST OF ABBREVIATIONS
ß-TCRP

l
M
A1
ADP
AKT
ALL
AML
APAF1
ATP
BAD
BAK
BAX
BCL-2
BCL-W
BCL-X
BCL-XL
BH
BH3
BID
BIM
BN-PAGE
BSA
CJ
CLL
CLP
ClpXP
CM
CML
CMP
CNS
CoA
CoQ
C-terminal
DCIP
DMEM
DMSO
DNA
DRP1
dsRED
DTT
E

Beta-transducin repeat containing E3 ubiquitin protein ligase
Delta
Microliter
Micromolar
BCL-2-related protein A1
Adenosine diphosphate
Protein kinase B
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Apoptotic protease activating factor 1
Adenosine triphosphate
BCL-2 antagonist of cell death
BCL-2 antagonist/killer
BCL-2-associated x protein
B cell lymphoma 2
BCL-2-like protein 2
BCL-2-like protein 1
BCL-2-related gene, long isoform
BCL-2 homology
BCL-2 homology 3
BH3-interacting-domain death agonist
BCL-2-interacting mediator of cell death
Blue native polyacrylamide gel electrophoresis
Bovine serum albumin
Cristae junction
Chronic lymphocytic leukemia
Common lymphoid progenitor
Protease specificity-enhancing factor
Cristae membrane
Chronic myelogenous leukemia
Common myeloid progenitor
Central nervous system
Coenzyme A
Cytochrome c oxidoreductase
Carboxyl-terminal
2,6-dichlorophenolindophenol
Dulbecco’s modified eagle medium
Dimethyl sulfoxide
Deoxyribonucleic acid
Dynamin-related protein
Discosoma sp. red fluorescent protein
Dithiothreitol
Embryonic day

x

EDTA
EGTA
ER
ETC
FADD
FBS
FBW7
FCCP
GFP
GMP
GSK-3
HBSS
HECT
HEPES
HM
HSC
IBM
IF1
IgG
IL
IMM
IMS
JAK
JNK
kD
LON
MAP
MCL-1
MEF
MFN
MgCl2
MIB
MnSOD
Mx1
NAD+
NADPH
NK
PDH
PEST
PI
PI3K
PMS
PMSF
PUMA
PVDF

Ethylene diaminetetraacetic acid
Ethylene glycol bis-(2-amino-ethylether)-N, N, N', N-tetraacetic
Endoplasmic reticulum
Electron transport chain
FAS-associated death domain
Fetal bovine serum
F-box and WD repeat domain containing 7, E3 ubiquitin protein
ligase
Carbonylcyanide-p-trifluoromethoxyphenylhydrazone
Green fluorescent protein
Granulocyte monocyte progenitor
Glycogen synthase kinase 3
Hank’s balanced saline solution
Homologous to the E6-AP carboxyl terminus
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
Heavy membrane
Hematopoietic stem cell
Inner boundry membrane
Inhibitory factor 1
Immunoglobulin G
Interleukin
Inner mitochondrial membrane
Inner membrane space
Janus kinase
c-Jun N-terminal kinases
Kilodalton
Lon peptidase
Mitogen-activated protein
Myeloid cell leukemia 1
Mouse embryonic fibroblast
Mitofusin
Magnesium chloride
Mitochondrial isolation buffer
Manganese superoxide dismutase
Interferon-induced GTP-binding protein
Nicotinamide adenine dinucleotide
Nicotinamide adenine dinucleotide phosphate
Natural Killer
Pyruvate dehydrogenase
Proline, glutamine, serine, and threonine
Propidium Iodide
Phosphoinositide 3 kinase
Phenazine methosulphate
phenylmethanesulfonylfluoride
P53-upregulated modulator of apoptosis
Polyvinylidene fluoride

xi

RNA
RNAi
ROS
SCF
SDS-PAGE
Ser
STAT
SV40
TIM
TOM
TNF
TPA
USP9X
UV

Ribonucleic acid
Ribonucleic acid interference
Reactive oxygen species
Stem cell factor
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Serine
Signal transducer and activator of transcription
Simian virus 40
Translocase of inner membrane
Translocase of outer membrane
Tumor Necrosis Factor
12Otetradecanoylphorbol13acetate
Ubiquitin specific peptidase 9, X-linked
Ultraviolet

xii

CHAPTER 1.

INTRODUCTION

The BCL-2 Family Proteins and Apoptosis
Apoptosis is an essential genetic program required in the regulation of
development and maintenance of homeostasis of animals. Dysregulation of apoptosis can
lead to a variety of human pathologies, including cancer, neurodegenerative, and
autoimmune diseases (Cory and Adams, 2002). Two programs that regulate apoptosis
merge to induce the activation of caspases, which are proteases responsible for the
demise of a cell. The extrinsic pathway involves the ligation of death receptors on the
surface of the cell. The death receptors (members of the tumor necrosis factor receptor
superfamily) contain an intracellular death domain that recruits and activates Caspase-8
(Youle and Strasser, 2008). Caspase-8 is recruited through the adaptor protein Fasassociated death domain (FADD), resulting in subsequent activation of effector caspases,
such as Caspase-3 (Youle and Strasser, 2008).
In many cell types, the extrinsic pathway for cell death does not involve BCL-2
family members or mitochondrial outer membrane permeabilization. The intrinsic cell
death pathway, however, is regulated by BCL-2 family members and focuses much of its
effort at the level of the mitochondria (Chipuk et al., 2010). It consists of both pro and
anti-apoptotic members that share a homology within four conserved regions called BCL2 homology domains (BH), which correspond to -helical segments (Danial and
Korsmeyer, 2004; Opferman, 2008) (Fig. 1.1). Anti-apoptotic BCL-2 family members
(such as BCL-2, BCL-XL, BCL-W, MCL-1, and A1) share all four BH domains and
possess a hydrophobic binding pocket that binds the BH3 domain of other family
members (Fig. 1.1). The pro-apoptotic BCL-2 family members can be subdivided into
two groups, the multidomain pro-apoptotic effectors (such as BAX and BAK) which
have three BH domains and the BH3-only molecules (such as BID, BAD, BIM, PUMA,
NOXA, etc.) which reside upstream of BAX/BAK activation (Cheng et al., 2001) (Fig.
1.1). Death signals activate and/or induce the BH3-only molecules through either
transcriptional regulation or post-translational modification (Chipuk et al., 2010). The
activated BH3 only proteins subsequently promote BAX and BAK oligomerization; a
process antagonized by anti-apoptotic BCL-2 family members (Cheng et al., 2001) (Fig.
1.2). Activation and oligomerization of BAX/BAK results in mitochondrial outer
membrane permeabilization (MOMP) that releases a variety of apoptogenic proteins,
such as cytochrome c, from the mitochondrial intermembrane space (Goldstein et al.,
2000) (Fig. 1.2). Cytochrome c then binds to APAF-1, changing its conformation so that
it can recruit Caspase-9. Once Caspase-9 is bound to APAF-1 it can activate itself. The
active Caspase-9 then cleaves the effector caspases, such as Caspase-3, resulting in the
orderly demise of a cell (Opferman and Korsmeyer, 2003) (Fig. 1.2).
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Figure 1.1. The BCL-2 Family
Reprinted by permission from Macmillan Publishers Ltd: Opferman, J.T., and
Korsmeyer, S.J. (2003). Apoptosis in the development and maintenance of the immune
system. Nat Immunol 4, 410-415.
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Figure 1.2. BCL-2 Family Mediated Apoptosis
The BCL-2 family integrates death signals from a variety of sources and regulates
mitochondria-dependent apoptosis. BH3-only family members act as sentinels for many
death stimuli and can be regulated by transcriptional and post-translational mechanisms,
allowing rapid response to changing cellular conditions. They can be directly sequestered
by antiapoptotic BCL-2 family members (e.g. BCL-2, BCL-XL, MCL-1, etc.). Upon
sufficient activation, BH3-only family members can mediate the activation of the
multidomain proapoptotics BAX and BAK either by a 'hit and run' interaction or by
relieving antiapoptotic antagonism of BAX and BAK allowing oligomerization. Upon
BAX and BAK oligomerization, the mitochondrial outer membrane is permeabilized
releasing a variety of apoptogenic substrates from the mitochondrial intermembrane
space, such as cytochrome c, into the cytosol. Released cytochrome c can complex with
APAF1 and Pro-Caspase-9 to form the apoptosome, which catalyzes Caspase-9
activation. Activated Caspase-9 can then trigger the activation of a downstream caspase
cascade leading to cell death. Reprinted by permission from Macmillan Publishers Ltd:
Opferman, J.T. (2008). Apoptosis in the development of the immune system. Cell Death
Differ 15, 234-242.
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Anti-apoptotic MCL-1
Mcl-1 was initially identified as an early-induced gene during TPA induced
differentiation in a human myeloid leukemia cell line (ML-1) (Kozopas et al., 1993).
MCL-1 shares sequence homology to BCL-2 in the carboxy-terminal region where it
contains three amphipathic alpha-helical segments; however, its amino-terminal region is
poorly conserved (Kozopas et al., 1993). The amino-terminus of MCL-1 is much longer
than that of any other anti-apoptotic BCL-2 family member and contains two PEST
sequences (Kozopas et al., 1993). In addition, at the carboxy-terminal end, it possesses a
membrane spanning domain consisting of 20 hydrophobic amino acids, flanked by
charged residues similar to BCL-2 (Kozopas et al., 1993). Deletion of either the aminoor carboxy-terminus of MCL-1 does not disrupt its ability to bind pro-apoptotic
molecules (Day et al., 2005).
During murine embryogenesis, MCL-1 expression is rapidly induced after
fertilization and peaks during the 2-cell through 8-cell stages and then decreases in
blastocysts (Sano et al., 2000). MCL-1 is expressed in human epithelial cells of the skin,
gastrointestinal tract, and pulmonary tissues, in cardiomyocytes, skeletal muscle,
hematopoietic cells, lymphocytes, uterus, adrenal cortex, sympathetic ganglia, pancreatic
islets, and hepatocytes (Krajewski et al., 1995). MCL-1 expression is also regulated by
growth factor signaling. Both mature lymphocytes and immature progenitors increase
MCL-1 expression in response to IL-7 stimulation (Opferman et al., 2003).
Hematopoietic stem cells also increase Mcl-1 mRNA after exposure to stem cell factor
(SCF) and IL-6 (Opferman et al., 2005). Conversely, withdrawal from IL-3 in BAF/3
cells results in decreased MCL-1 expression (Maurer et al., 2006).
MCL-1 is predominantly localized to the mitochondrial membrane, with some
distribution also detectable in ER membranes (Germain and Duronio, 2007; Yang et al.,
1995). Membrane association of MCL-1 depends on the presence of its hydrophobic
carboxy-terminus which serves as a transmembrane domain (Yang et al., 1995). The
amino-terminus of MCL-1 also regulates its association with mitochondrial membranes;
however, the underlying mechanism is unclear (Germain and Duronio, 2007).
Additionally, several reports claim that MCL-1 is localized both to the mitochondria and
the nucleus, where it interacts with PCNA and inhibits cells from progressing through Sphase (Fujise et al., 2000).
MCL-1 Anti-apoptotic Function
In-vitro binding assays with recombinant anti-apoptotic BCL-2 family members
and peptides corresponding to the BH3 domains of pro-apoptotic molecules demonstrate
that MCL-1 selectively binds pro-apoptotic family members (Chen et al., 2005b). MCL1 displays selective binding for pro-apoptotic molecules BIM, PUMA, NOXA, and BAK
but does not interact with BAD (Chen et al., 2005b; Opferman et al., 2003).
Interestingly, in-vitro competitive binding assays indicate that MCL-1 and A1 are the
only anti-apoptotic family members with the ability to interact with NOXA (Chen et al.,
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2005b). Moreover, BAK selectively interacts with MCL-1 and BCL-X but not BCL-2
(Chen et al., 2005b). The interaction between MCL-1 and BAK has also been confirmed
by co-immunoprecipitation of proteins derived from mitochondria (Willis et al., 2005).
Another report indicated that MCL-1 interacts with BAX, where it protects hematopoietic
cells from apoptosis under a variety of death stimuli including etoposide, UV irradiation,
and growth factor withdrawal (Zhou et al., 1997).
MCL-1 and Cell Survival
BCL-2 family members play specific roles in regulating homeostasis during
various stages of hematopoiesis (Fig. 1.3). The roles of anti-apoptotic BCL-2 family
members during hematopoiesis have been identified through loss of function studies.
Bcl-2-deletion results in viable mice that display an increase in apoptosis of mature B and
T lymphocytes after 3 weeks of age (Veis et al., 1993). Bcl-XL-deficient embryos die at
embryonic day 13 due to neuronal and erythroid defects (Motoyama et al., 1995).
Conditional deletion of Bcl-XL in the erythroid lineage results in severe anemia and
reduces the number of red blood cells significantly, indicating that BCL-XL is important
during erythropoiesis (Wagner et al., 2000).
MCL-1 is unique among pro-survival BCL-2 molecules in that it is essential for
early (E3.5) embryonic development and also has a critical role during multiple stages of
hematopoiesis and lymphopoiesis (Rinkenberger et al., 2000) (Fig. 1.3). Conditional
deletion of Mcl-1 during early thymocyte development, using Lck-Cre, results in no
viable, mature, deleted T cells (Opferman et al., 2003). Additionally, deletion of Mcl-1
during early B cell development, using CD19-Cre, results in death at the pro-B stage
(Opferman et al., 2003). This suggests that MCL-1 is critical for the development of
lymphocytes. Furthermore, MCL-1 is also required for the maintenance of mature
lymphocytes (Dzhagalov et al., 2008; Opferman et al., 2003).
MCL-1 is also essential during the early stages of hematopoiesis (Fig. 1.3).
Inducible deletion of Mcl-1 in hematopoietic lineages results in rapid hematopoietic
failure (Opferman et al., 2005). The earliest populations lost are the hematopoietic stem
cells (HSCs), common myeloid progenitors (CMPs), and common lymphoid progenitors
(CLPs) (Opferman et al., 2005). Moreover, during myelopoiesis, MCL-1 is required for
the differentiation of granulocyte precursors to mature neutrophils (Dzhagalov et al.,
2007; Steimer et al., 2009). In contrast, deletion of Mcl-1 in the myeloid lineage does not
block the development of mature macrophages but is important for survival during
effector function (Dzhagalov et al., 2007; Steimer et al., 2009). These data underscore an
essential role for MCL-1 in promoting the survival and differentiation of many
hematopoietic lineages.
In addition to hematopoiesis, MCL-1 is also required during the development of
the central nervous system (CNS) (Arbour et al., 2008). Conditional deletion of Mcl-1 in
the forebrain results in embryonic lethality at day 15, whereas, deleting Mcl-1 earlier in
CNS development results in lethality at embryonic day 12.5 (Arbour et al., 2008).
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Figure 1.3. Apoptotic Checkpoints during Hematopoiesis
All blood cell lineages arise from a hematopoietic stem cell (HSC) that is capable of selfrenewal and has an indefinite life-span. HSCs give rise to multi-potent progenitors
(MPPs) which still retain the ability to give rise to all blood cell lineages, but lack longterm self-renewal capacity. MPPs can produce two progenitors, common myeloid
progenitors (CMPs) and common lymphoid progenitors (CLPs). CLPs can produce the
lymphoid lineages (B, T, and perhaps NK cells). CMPs produce at least two other
oligopotent progenitor populations, the megakaryocyte erythroid progenitor (MEP) that
produce red blood cells (erythrocytes), megakaryocytes (generates platelets), and the
granulocyte monocyte progenitor (GMP), which produces neutrophils and macrophages.
Listed beside each differentiation step or progenitor population are the known antiapoptotic regulators that promote the survival of the given population. Anti-apoptotic
MCL-1 has multiple checkpoints as has been illustrated to be critical for the survival of
several multipotent and oligopotent progenitor populations (HSC, CMP, CLP, and GMP)
and has been shown to be critical for the differentiation of granulocytes, but interestingly
not the monocyte lineage. A1-A, a murine ortholog of BFL-1, has also been shown to
play an important role in promoting neutrophil survival in response to stress, but is not
absolutely required for survival (indicated by open arrowhead). In the erythroid lineage,
BCL-XL is the essential survival molecule, but unpublished data indicates that MCL-1
may also play an essential role during early differentiation. In the megakaryocytic
lineage it appears that while neither MCL-1 nor BCL-XL is solely responsible for
survival, the two pro-survival molecules appear to have overlapping functions (indicated
by open arrowheads) in promoting megakaryocyte survival. The critical anti-apoptotic
regulators of some lineages including NK cells are still uncertain.
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MCL-1 Regulation
Mcl-1 is regulated at the transcriptional, translational, and post-translational
levels. Growth factors and cytokines including interleukin-2 (IL-2), interleukin-7 (IL-7),
and granulocyte-macrophage colony-stimulating factor (GM-CSF) induce Mcl-1
transcription (Opferman et al., 2005; Opferman et al., 2003; Wang et al., 1999).
Likewise, a variety of signaling pathways including MAP kinases, PI3K/Akt, and
JAK/STAT modulate elements in Mcl-1’s promoter to increase transcription (Huang et
al., 2000; Wang et al., 1999). In addition, Mcl-1 mRNA translation is regulated by
mTORC1 (Mills PNAS 2008).
MCL-1 protein expression is tightly regulated at the post-translational level.
MCL-1 phosphorylation in response to cellular signaling is a critical control point for
regulating its anti-apoptotic function. However, there is evidence of phosphorylation
both promoting and inhibiting MCL-1 anti-apoptotic activity depending on the type of
death stimuli. For example, oxidative stress promotes JNK-mediated phosphorylation of
human MCL-1 at two residues (Ser-121 and Thr-163) resulting in a loss of anti-apoptotic
function (Inoshita et al., 2002). In contrast, phosphorylation at the same residue (Thr163) blocks ubiquitinylation, thus, extending the protein half-life and cellular survival
(Domina et al., 2000; Li et al., 2007). MCL-1 phosphorylation is also potently regulated
by growth factor availability. For example, cytokine withdrawal results in
phosphorylation of MCL-1 on Ser-159 by GSK-3 thereby facilitating its degradation
(Maurer et al., 2006).
The short half-life (~2 hours) of MCL-1 distinguishes it from other anti-apoptotic
BCL-2 family members; the amino-terminus possess several proline-glutamic acidserine-threonine (PEST) regions, a common feature of rapidly degraded proteins.
Nevertheless, the PEST regions are dispensable for MCL-1 protein turnover (Akgul et al.,
2000). MCL-1 undergoes both ubiquitin-dependent and ubiquitin-independent
degradation (Stewart et al., 2010a; Zhong et al., 2005). Three E3 ligases have been
implicated in MCL-1 ubiquitinylation. The HECT-domain containing MULE targets
MCL-1 for degradation by the proteosome (Zhong et al., 2005). Whether MULEdependent ubiquitinylation of MCL-1 occurs in healthy cells or apoptotic cells remains
controversial (Hao et al., 2012; Zhong et al., 2005). Both ß-TRCP and FBW7 are SKP1cullin-1-F-box (SCF) complex E3 ligases that ubiquitinylate MCL-1 in a
phosphorylation-dependent manner (Ding et al., 2007; Inuzuka et al., 2011).
Furthermore, the deubiquitinase, USP9X, binds to MCL-1 and removes polyubiquitin
chains, thus, stabilizing MCL-1 protein levels (Schwickart et al., 2010).
MCL-1 and Cancer
Dysregulated MCL-1 expression can inappropriately promote cell survival. For
example, transgenic expression of MCL-1 in mice can lead to tumorigenesis and
hyperplasia (Matsushita et al., 2003; Zhou et al., 2001). MCL-1 is overexpressed and
often associated with chemotherapeutic resistance in many different cancers including
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acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic
myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and multiple
myeloma, (Kaufmann et al., 1998; Pepper et al., 2008; Wei et al., 2006). In addition,
MCL-1 is upregulated in a variety of solid tumors including hepatocellular carcinoma,
pancreatic cancer, testicular cancer, cervical cancer, lung cancer, and melanoma (Chung
et al., 2002; Sano et al., 2005; Sieghart et al., 2006; Song et al., 2005; Zhuang et al.,
2007). Furthermore, the MCL-1 locus is frequently amplified in human cancers
(Beroukhim et al., 2010). The expanding variety of malignancies that display high levels
of MCL-1 expression illustrate the importance of understanding how MCL-1 expression
and function are regulated.
Cancer cells often violate a number of cellular checkpoints including cell cycle
arrest and the induction of apoptosis. For that reason, they often become dependent on
anti-apoptotic molecules to bypass programmed cell death (Certo et al., 2006). As a
result, small molecules that antagonize these pro-survival molecules have been developed
as a therapeutic approach. ABT-737 is a small molecule that inhibits BCL-2 and BCLXL and promotes cell death. However, high levels of MCL-1 can contribute to resistance
to ABT-737 (Certo et al., 2006). Consequently there has been much effort to find a small
molecule that is capable of blocking the protective effects of MCL-1(Nguyen et al.,
2007).
Dynamic Structure of Mitochondria
Mitochondria are dynamic organelles constantly undergoing fission and fusion to
maintain a cellular network important for their function (Detmer and Chan, 2007) (Fig.
1.4). Under normal conditions, fission and fusion are balanced to support normal
mitochondrial morphology; however, the disturbance of this equilibrium leads to
dramatic alterations in their shape. For example, increases in fusion result in elongated
mitochondria that are extremely interconnected (Smirnova et al., 2001) (Fig. 1.5).
Conversely, cells with a high fission rate produce many small, fragmented mitochondria
(Chen et al., 2003) (Fig. 1.5).
Internal Structure of Mitochondria
Mitochondria possess a selectively-permeable outer membrane and an inner
membrane consisting of a larger surface area that folds and forms invaginations called
cristae (Frey and Mannella, 2000). The two membranes surround two aqueous spaces,
the matrix, where the TCA cycle enzymes and mitochondrial genome are located, and the
intermembrane space, where cytochrome c, resides. Recent advances in electron
microscopy techniques have revealed that the mitochondrial inner membrane can be
subdivided into distinct domains: the inner boundary membrane, the cristae membrane,
and the cristae junctions (Frey and Mannella, 2000) (Fig. 1.6). The inner boundary
membrane consists of the areas where the inner membrane juxtaposes to the outer
membrane; whereas the cristae membrane entwines and extends, increasing the surface
area of the inner membrane (Mannella, 2006). The cristae junctions are constricted
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Figure 1.4. Mitochondrial Dynamics
Mitochondrial fusion and fission control mitochondrial number and size. With fusion,
two mitochondria become a single larger mitochondrion with continuous outer and inner
membranes. Conversely, a single mitochondrion can divide into two distinct
mitochondria by fission. Reprinted by permission from Macmillan Publishers Ltd:
Detmer, S.A., and Chan, D.C. (2007). Functions and dysfunctions of mitochondrial
dynamics. Nat Rev Mol Cell Biol 8, 870-879.

Figure 1.5. Mitochondrial Morphology
Mitochondrial length, size and connectivity are determined by the relative rates of
mitochondrial fusion and fission. In wild-type cells (shown in the central panel),
mitochondria form tubules of variable length. In the absence of mitochondrial fusion (for
example, in mitofusin (Mfn)-null cells (shown in the left panel), which lack MFN1 and
MFN2), unopposed fission results in a population of mitochondria that are all
fragmented. Conversely, decreased fission relative to fusion, for example, in DRP1 K38A
cells (shown in the right panel), which have a dominant-negative form of dynaminrelated protein-1 (DRP1), results in elongated and highly interconnected mitochondria.
Scale bar represents 10 μm. Reprinted by permission from Macmillan Publishers Ltd:
Detmer, S.A., and Chan, D.C. (2007). Functions and dysfunctions of mitochondrial
dynamics. Nat Rev Mol Cell Biol 8, 870-879.
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Figure 1.6. Mitochondrial Ultrastructure
The diagram indicates the different regions of the inner membrane. CJ, cristae junction;
CM, cristae membrane; IBM, inner boundary membrane; IM, inner membrane; IMS,
intermembrane space; OM, outer membrane. Reprinted by permission from Macmillan
Publishers Ltd: Detmer, S.A., and Chan, D.C. (2007). Functions and dysfunctions of
mitochondrial dynamics. Nat Rev Mol Cell Biol 8, 870-879.
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constricted regions that separate the inner membrane boundary from the cristae
membrane (Mannella, 2006) (Fig. 1.6). Furthermore, immunoelectron microscopy has
determined that proteins are differentially distributed among the different domains. For
example, translocase of inner membrane proteins are localized to the inner boundary
membrane whereas proteins of the respiratory complexes are localized to the cristae
membranes (Vogel et al., 2006).
Regulators of Fusion and Fission
The major mediators of mitochondrial fission and fusion are evolutionarily
conserved and consist of proteins from the dynamin family of GTPases (Okamoto and
Shaw, 2005). Mitochondrial fusion incorporates fusion of both the outer and inner
mitochondrial membranes. In mammalian cells, the early steps of mitochondrial fusion
are regulated by Mitofusins, which are GTPases that reside on the outer mitochondrial
membrane (Chen et al., 2003). There are two mitofusin homologues, Mitofusin 1 (Mfn1)
and Mitofusin 2 (Mfn2), which have similar roles in mitochondrial fusion. Both Mfn1
and Mfn2 engage in homotypic interactions on adjacent mitochondria and through GTP
hydrolysis bring the two mitochondria together (Koshiba et al., 2004). Cells that are
deficient in both Mfn1 and Mfn2 have dramatically reduced levels of mitochondrial
fusion (Chen et al., 2005a; Chen et al., 2003). Together with the mitofusins, OPA1 is
another dynamin family GTPase that is critical for mitochondrial fusion. OPA1 localizes
to the inner mitochondrial membrane and intermembrane space and is crucial for fusion
of the inner mitochondrial membrane (Griparic et al., 2004). The OPA1 gene undergoes
alternative splicing to produce eight mRNA isoforms (Delettre et al., 2001).
Additionally, OPA1 is proteolytically cleaved into additional isoforms that are necessary
for mitochondrial fusion (Ishihara et al., 2006).
Drp1 is the member of the dynamin family of GTPases that regulates the
opposing process of mitochondrial fission in mammalian cells. Drp1 localizes both to the
cytosol and to the mitochondrial outer membrane (Smirnova et al., 2001). Drp1 forms
oligomers around the mitochondrion, constricts it and utilizes GTP hydrolysis to drive
mitochondrial division (Praefcke and McMahon, 2004). Expression of a dominantnegative Drp1 in cells results in inhibition of endogenous Drp1 and excessive
mitochondrial elongation (Lee et al., 2004; Smirnova et al., 2001). Based on these
results, mitochondrial morphology is a highly dynamic process that is regulated by the
opposing processes of fission and fusion.
Biological Functions
Perhaps the most important biological consequence of fission and fusion is
maintenance of a healthy mitochondrial population. Mitochondria produce a substantial
amount of reactive oxygen species (ROS); therefore, their genome is remarkably
susceptible to DNA damage. Mitochondria protect themselves from accumulating
excessive damage through fusion, which facilitates the exchange of lipid membranes and
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the mitochondrial genome between organelles thereby allowing damaged mitochondria to
be restored to normal. Whereas, fission is necessary to increase mitochondrial number
and allow distribution to daughter cells during cell division (Chen and Chan, 2005; Mitra
et al., 2009). Imbalances in fission and fusion lead to a variety of cellular and
mitochondrial defects (Bleazard et al., 1999; Chen et al., 2003). For example, normal
mitochondrial fusion is required for cell growth, efficient oxidative phosphorylation and
ATP production (Chen et al., 2005a). Thus, the integrity of the mitochondrial network is
intimately associated with cellular fate and bioenergetics.
The BCL-2 Family and Dynamics
In addition to their role in apoptosis, BCL-2 family proteins have also been shown
to regulate mitochondrial dynamics (Autret and Martin, 2009). However, the
mechanisms and functional impact through which individual BCL-2 proteins influence
mitochondrial dynamics remains elusive, as in some cases the same molecules can
promote both fission and fusion of the mitochondrial network. For example, the
expression of anti-apoptotic BCL-XL in various cell types promoted mitochondrial fusion
and interacted with Mfn2 (Delivani et al., 2006). In cortical neurons, BCL-XL expression
increased both fission and fusion (Berman et al., 2009). Additionally, when overexpressed, the pro-apoptotic effectors BAX and BAK induced mitochondrial fission
(Sheridan et al., 2008); however, Bax and Bak doubly-deficient cells also exhibited a
fragmented mitochondrial network and had decreased rates of mitochondrial fusion
(Karbowski et al., 2006). In a cell free system used to study mitochondrial fusion, the
addition of recombinant BAX promoted fusion in an Mfn2-dependent manner (Hoppins
et al., 2011b). The fusogenic function of BAX was limited to its monomeric form as
oligomeric BAX abrogated its ability to promote fusion (Hoppins et al., 2011a).
Direct interaction between Mfn2 and some of the BCL-2 family members, such as BCLXL and BAX, mechanistically demonstrates how BCL-2 proteins regulate mitochondrial
dynamics. To better clarify their role, it is important to separate the apoptotic functions
of the BCL-2 family members from their ability to regulate mitochondrial
morphogenesis.
It is significant to note that the process of mitochondrial fission and fusion has
also been shown to play a role in apoptosis. Studies have demonstrated that
mitochondrial fragmentation can occur early during apoptosis (Frank et al., 2001). To
what extent the fission machinery directly regulates apoptosis is still unclear. For
example, the amount of mitochondrial fragmentation during apoptosis was shown to
depend on Drp1, while reduced Drp1 expression reduced cytochrome c release
(Breckenridge et al., 2003; Frank et al., 2001). However, other studies found that Drp1
inhibition did not affect cell death (Estaquier and Arnoult, 2007; Sheridan et al., 2008).
The role mitochondrial fusion may play in apoptosis is also not well understood. Some
evidence has suggested that inhibition of Mfn1- and Mfn2-induced mitochondrial
fragmentation and sensitized cells to death-inducing agents (Jahani-Asl et al., 2007;
Sugioka et al., 2004). Overexpression of Mfn2 delayed BAX activation and the release
of cytochrome c (Neuspiel et al., 2005). Likewise, increased Mfn2 expression protected
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neurons from apoptotic stimuli (Jahani-Asl et al., 2007). The link between regulators of
inner mitochondrial membrane fusion and apoptosis has also been investigated. OPA1
expression was able to protect cells from cell death induced through the mitochondrial
pathway (Frezza et al., 2006). In contrast another study found that expression of Mfn1,
Mfn2, or OPA1 had no protective effect on cell death and that cytochrome c release
occurs in mitochondria with a reticular network (Sheridan et al., 2008).
Supermolecular Protein Complexes in the Inner Mitochondrial Membrane
In addition to being the critical organelle at which the commitment to intrinsic
apoptosis is made, mitochondria are also important for the production of energy by
oxidative phosphorylation. This process includes electron transport chain complexes that
pass electrons generated from the Krebs cycle in a stepwise method to reduce molecular
oxygen and produce water. Protons are simultaneously pumped out of the mitochondrial
matrix and into the cytosol generating an electrochemical gradient across the
mitochondrial inner membrane (Mitchell, 1961) (Fig. 1.7). The protons then diffuse back
into the mitochondria through the F1F0-ATP synthase to generate ATP from ADP
(Wallace, 1999) (Fig. 1.7). The complexes of the electron transport chain are massive,
multi-subunit complexes and consist of NADH dehydrogenase (complex I), succinate
dehydrogenase (complex II), ubiquinone oxidoreductase (complex III), and cytochrome c
oxidase (complex IV) (Fig. 1.7). To increase the efficiency of oxidative phosphorylation,
the inner membrane is folded to generate cristae, which amplifies the enzymes
participating in this metabolic process.
Respiratory Supercomplexes
The structural organization of the respiratory chain complexes I-IV have
historically included the lateral diffusion of the individual complexes in the inner
membrane, where electron transfer depends on the transient collision of these complexes
(Lenaz and Genova, 2007) (Fig. 1.7). However, more recently blue-native gel
electrophoresis (BN-PAGE) has revealed that these complexes are organized into
megadalton supramolecular complexes, called supercomplexes. These supercomplexes
are assemblies of the different respiratory components and are capable of respiration
(Acin-Perez et al., 2008) (Fig. 1.8). Additionally, genetic mutations encoding one
subunit of a complex result in the de-stabilization of other complexes (Acin-Perez et al.,
2008). Likewise, the stability of the supercomplexes also depends on cardiolipin, an
abundant phospholipid in the IMM (Pfeiffer et al., 2003). It is hypothesized that the
formation of respiratory supercomplexes increases the efficiency of electron transfer
between the complexes; therefore, reducing the generation of unstable reactive oxygen
radicals.
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Figure 1.7. Oxidative Phosphorylation
Electrons derived from the Krebs cycle are passed through the electron transport
complexes to reduce oxygen to water. Simultaneously, protons are pumped out of the
mitochondrial matrix, generating an electrochemical gradient. Protons then diffuse back
into the matrix through the F1F0-ATP synthase, producing the energy required to make
ATP from ADP. Reprinted by permission from Macmillan Publishers Ltd: Acin-Perez,
R., Fernandez-Silva, P., Peleato, M.L., Perez-Martos, A., and Enriquez, J.A. (2008).
Respiratory active mitochondrial supercomplexes. Mol Cell 32, 529-539.

Figure 1.8. Respiratory Supercomplexes
Model for the organization of different subtypes of respiratory supercomplexes. The
respiratory complexes are assembled into supercomplexes of various types. Reprinted by
permission from Macmillan Publishers Ltd: Acin-Perez, R., Fernandez-Silva, P., Peleato,
M.L., Perez-Martos, A., and Enriquez, J.A. (2008). Respiratory active mitochondrial
supercomplexes. Mol Cell 32, 529-539.
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F1F0-ATP Synthase Dimers and Oligomers
The F1-F0-ATP synthase (ATP synthase) is composed of a soluble catalytic unit,
F1, located inside the mitochondrial matrix, and a membrane-bound unit, F0, which
anchors the enzyme in the inner membrane and mediates the flow of protons through the
membrane. ATP synthase exists in monomers but also forms supercomplexes containing
homo-dimers and homo-oligomers (Schagger and Pfeiffer, 2000). The ATP synthase
dimers and oligomers are necessary for generation of mitochondrial cristae and increase
the efficiency of ATP production (Paumard et al., 2002; Strauss et al., 2008). The
dimerization of ATP synthase predominantly involves the F0 domains but also includes
the F1 domains. The F0 domains are closely assembled, whereas the F1 have a distant
association. This arrangement produces a 40º angle between the monomers, curving the
lipid membrane, which is thought to be responsible for the structure of the cristae
(Minauro-Sanmiguel et al., 2005). In yeast, deletion of F0 subunits e and g abolish
dimerization and lead to cristae morphology abnormalities (Paumard et al., 2002). The F1
regions of each monomer are indirectly associated by inhibitory factor 1 (IF1), which
connects the two monomers (Cabezon et al., 2003).
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CHAPTER 2.

MATERIALS AND EXPERIMENTAL PROCEDURES*
Cells and Cell Culture

SV40-transformed wild-type (wt) and Mcl-1-deficient mouse embryonic
fibroblasts (MEFs) have been previously described (Opferman et al., 2003). Mcl-1f/f
Rosa-ERCreT2 and wt Rosa-ERCreT2 MEFs were generated from E12.5 embryos and
SV40-transformed. To induce Mcl-1-deletion, the MEFs were treated for 48 hours with
100 nM (4-hydroxy)-tamoxifen (Sigma) in culture media to induce Cre expression.
HEK293T cells and human non-small cell lung cancer (NSCLC) cells were obtained
from American Type Culture Collection. All cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen) supplemented with 5% fetal bovine serum, 20mM
L-glutamine (Gibco) and 10mM HEPES (Gibco). Cells grown in galactose were grown
in glucose-free Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented
with 10% fetal bovine serum, 2mM glutamine, and 10mM galactose.
Plasmids, Expression Constructs, and Generation of Mutants
All Mcl-1 constructs were developed using mouse Mcl-1 cDNA. The mutant
Mcl-1 , in which arginines 5 and 6 were replaced by alanines, was generated by sitedirected mutagenesis (Stratagene). The N-terminal 67 amino acids of MCL-1 (MCL-1 N)
and the C-terminal 22 amino acids (MCL-1 C) were deleted by polymerase chain reaction
(PCR). The MCL-1-hBCL-2 chimera was made by fusing the N-terminal 50 amino acids
of MCL-1 to full-length human BCL-2 by PCR. The mutant Mcl-1Matrix was generated by
fusing amino acids 1-58 of N. crassa ATP-synthase to Mcl-1 N. Mitochondrial
morphology and fusion were measured using matrix-localized photoactivatable-GFP
(Karbowski et al., 2004) and Mito-DsRed (Clontech). MCL-1ATG1 was generated by
PCR amplification using 5' -cgagctcgaattctagtttggcctgcggagaaac -3' (sense) and 5'gcatatctaataagataggcgggcggatccgca - 3' (antisense). The non-canonical mRNA splicing
mutant Mcl-1SD;SAmut was generated by mutating nucleotide 52 from G to A changing the
amino acid sequence from glycine to serine and mutating nucleotide 189 from G to T
creating a silent mutation and maintaining the amino acid valine (Kojima et al., 2010).
The PCR primers for nucleotide 52 are forward primer (5’aacctgtactgcggcagcgccagcctcggcgcg-3’) and reverse primer (5’cgcgccgaggctggcgctgccgcagtacaggtt-3); and for nucleotide 189 are forward primer (5’cccggccgccgcccgttggcgccgaggaccccg-3’) and reverse primer (5’cggggtcctcggcgccaacgggcggcggccggg-3’).
OM







*
Reprinted with permission. Perciavalle, R.M., Stewart, D.P., Koss, B., Lynch, J.,
Milasta, S., Bathina, M., Temirov, J., Cleland, M.M., Pelletier, S., Schuetz, J.D., et al.
(2012). Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples
mitochondrial fusion to respiration. Nature Cell Biology 14, 575-583.
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Ecotropic Retroviral Production and Cell Transduction
Ecotropic retroviruses were produced by co-transfection of retroviral expression
plasmids in 293T cells with packaging plasmids (pMD-old-Gag-Pol and pCAG4-Eco)
using FuGene6 (Roche Applied Bioscience).
Western Blotting, Co-immunoprecipitation, and Antibodies
For immunoblot analysis, cells were lysed in Flag Lysis Buffer (50mM Tris-HCl
pH 7.4, 150mM NaCl, 1% TritonX-100, 1mM EDTA) containing complete protease
inhibitors (Roche) on ice for 30 minutes. Whole cell lysates (WCL) were cleared by
centrifugation and protein concentrations were determined by BCA assay. For coimmunoprecipitation studies, whole cell lysates (WCLs) were pre-cleared and then
coupled with both anti-BIM short and anti-BIM long rat monoclonal antibodies
(Millipore) or rat IgG (Santa Cruz Biotechnology) for 1 hour then precipitated with
protein A/G-plus agarose (Santa Cruz Biotechnology). Immunocomplexes were
recovered, washed, and resuspended in sample buffer. Immunocomplexes and postimmunoprecipitated supernatants were subjected to electrophoresis using Bis-Tris gels
(Invitrogen), transferred to PVDF (Millipore) and developed using Western Lightning
(Perkin Elmer). The following antibodies were used: anti-MCL-1 (Rockland
Immunochemical), anti-BIM (BD Biosciences), anti-Tim50 (Abcam), anti-Tom40 (Santa
Cruz), anti-Prohibitin1 (Abcam), anti-Opa1 (BD Biosciences), anti-MnSOD (BD
Biosciences), anti-PDI (BD Biosciences), anti-hBCL-2 (Clone 6C8, gift of S.
Korsmeyer), anti-mBCL-2 (Clone 3F11, gift of S. Korsmeyer), anti-Complex II subunit
70 (MitoSciences), anti-Complex IV subunit II (Mitosciences), anti-Complex I subunit
NDUFA9 (MitoSciences), anti-Pyruvate dehydrogenase (Cell Signaling) and anti-Actin
mouse monoclonal (Millipore), Complex I, anti-NDUFA9 (Molecular Probes); Complex
II, anti-Fp70 (Molecular Probes); Complex III, anti-Core 2 (Molecular Probes); Complex
IV, anti-Cox I (Molecular Probes); ATP Synthase, anti-5A1 (Proteintech Group); ATP
Synthase, anti-5B (Santa Cruz Biotechnology); ATP Synthase, anti-gamma (GeneTex);
ATP Synthase, anti-OSCP (Santa Cruz Biotechnology).
Cell Death Experiments
Both wt Mcl-1 Rosa-ERCreT2 MEFs and Mcl-1f/f Rosa-ERCreT2 MEFs stably
expressing murine stem cell virus (MSCV)-puro vector, wt MCL-1, MCL-1OM, MCL1Matrix, or hBCL-2 were treated with tamoxifen for 48 hours and treated with etoposide or
staurosporine (Calbiochem). Cell viability was determined by staining with Annexin-VFITC and propidium iodide (PI) (BD Biosciences) and flow cytometry (FACSCalibur,
BD Biosciences).
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RNAi Experiments
For RNA-mediated interference (RNAi), MEFs were plated in Opti-MEM media
(Invitrogen) and transfected with respective 70 nM Stealth siRNAs (Invitrogen) specific
for mouse Tom40 and Tim50 using Lipofectamine RNAi-Max (Invitrogen). Six hours
after transfection media was replaced with complete DMEM media. Seventy-two hours
after transfection cells were collected, lysed and immunoblotted. Stealth siRNA
sequences were: TOM40: ACUGAACAACUGGUUGGCUACAGUA,
CCCUCUGUAUGAAAUAGUCAUCUUC,
GAAGAUGACUAUUUCAUACAGAGGG; TIM50:
GCCCUACUACCAGCCACCUUAUACA,
UGUAUAAGGUGGCUGGUAGUAGGGC,
UCAAGACCAUUGCACUGAACCAAGU
Measurement of Superoxide Anion
MitoSOX-red (Invitrogen) was used to measure reactive oxygen species (ROS) in
SV40-transformed wt Mcl-1 Rosa-ERCreT2 MEFs and Mcl-1f/f Rosa-ERCreT2 MEFs
expressing MSCV-puro vector, wt MCL-1, MCL-1OM, MCL-1Matrix, and hBCL-2. Cells
were treated with 5μM MitoSOX for 30 minutes. at 37°C and fluorescence measured by
flow cytometry. Antimycin A (Sigma) (10 nM), which induces superoxide through the
inhibition of complex III, was used as a positive control.
Isolation and Purification of Mouse Liver Mitochondria
Mouse livers were homogenized in Mito Isolation Buffer (MIB) buffer (200mM
Manitol, 68mM Sucrose, 10mM Hepes-KOH pH 7.4, 10mM KCl, 1mM EDTA, 1mM
EGTA. 0.1% BSA). Mitochondria were isolated using differential centrifugation and
were purified using a Percoll-gradient consisting of 70% percoll, overlayed by 30%
Percoll (Pierce) in 5mM MOPS and 0.3M mannitol. Protein content was determined by
Bradford assay (BioRad).
Subcellular Fractionation and Isolation of Heavy Membrane from Cells
Cells were swollen in 220mM Mannitol, 70mM Sucrose, 10mM Hepes-KOH (pH
7.4) for 30 minutes on ice. Cells were homogenized 30 times with a 30 gauge needle.
The non-lysed cells and nuclei were sedimented by centrifugation at 600xg for 10
minutes and disposed. The supernatant was centrifuged at 5,500xg for 15 minutes and
the pellet was the heavy membrane fraction. The supernatant was centrifuged at
100,000xg for 30 minutes and the soluble fraction contains the purified cytosolic fraction.
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Proteolysis of Heavy Membrane Fraction
The heavy membrane (HM) fraction was isolated from cells or mouse liver and
protein concentration determined by Bradford assay. HM (40ug) were treated with the
following treatments: proteinase K (0.2mg/ml), 20mM KCl (osmotic shock), 1% SDS
(membrane solubilization) for 30 minutes on ice. Proteins were precipitated with
tricholoroacetic acid (Sigma).
Oxygen Consumption
Respiration was measured in intact cells (64,000/well) seeded in poly-L-lysinecoated plates using the XF24 analyzer (Seahorse Bioscience) (Ferrick et al., 2008). After
5 hours, the cells were loaded into the machine to determine the oxygen consumption rate
(OCR). Respiration was measured sequentially after addition of 0.5μM oligomycin,
0.5μM FCCP, and 0.5μM rotenone. After each injection, OCR was measured (3
minutes), the medium mixed (2 minutes), and measured (3 minutes).
Alkali Wash
Purified mouse liver mitochondria were sonicated (40W for 15 seconds, twice) on
ice and then centrifuged at 10,000xg for 10 minutes to remove intact mitochondria. The
supernatant was centrifuged at 100,000xg for 30 minutes and the supernatant is the
soluble fraction. The pellet was treated with 0.1M sodium carbonate (pH 11.5) in MIB
buffer for 30 minutes on ice and then centrifuged at 100,000xg for 30 minutes and
supernatant and pellet collected.
Mitochondria Subfractionation
Mitochondria were swollen on ice for 30 minutes in 14 ml of 10mM KH2PO4 (pH
7.4). One-third volume of 1.8M sucrose, 10mM MgCl2 was added on ice for 30 minutes
to shrink the mitochondria. Mitochondria were sonicated (4 Amps for 5 seconds) in 2.5
ml aliquots then centrifuged at 12,000xg for 10 minutes to get supernatant 1 and pellet 1.
Supernatant 1 was then spun at 100,000xg for 1 hour and the pellet 2 is the OM. Pellet 1
was resuspended in 7ml of 1.8M sucrose, 10mM MgCl2 on ice for 5 minutes and
centrifuged at 5,500xg for 15 minutes and pellet 3 is the mitoplast.
Cellular ATP
ATP assays were performed using the ATP Bioluminescence Assay Kit HSII
(Roche) following the manufacturer’s instructions. Briefly, cells were counted in
triplicate and washed in PBS. Cells (0.5 x 106/ml) were resuspended in lysis buffer (5
minutes Lysed cells were incubated at 100 for 2 minutes, centrifuged at
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10,000xg for 5 minutes. Cell lysates (50 l ) were diluted in 50l of dilution buffer, and
100μl of luciferase reagent was added. The luminescence was measured using a
Luminometer (Biotek Synergy) and ATP concentration was determined by comparing
values to a standard curve.
Mitochondrial Fusion Assay and Image Analysis
Cells were grown in 4-well chambers and were transiently-transfected using
Fugene6 with a photoactivatable-GFP targeted to the mitochondrial matrix (Karbowski et
al., 2004). Images were captured using a Marianas spinning disk confocal (SDC) imaging
system consisting of a Zeiss Axio Observer (Carl Zeiss MicroImaging) inverted
microscope with motorized XYZ stage, a CSU-X confocal head (Yokogawa Electric
Corporation), LaserStack laser launch and Vector laser scanner head (Intelligent Imaging
Innovations-3i). Images were collected using a Zeiss Plan-Apochromat 63x 1.4 NA oil
objective and Evolve 512 EMCCD camera (Photometrics). 3-D time-lapse images of the
cells were acquired from the top to the bottom of mitochondria with 0.4μm z-sections
with varying time-intervals (10 initial frames at every 2 minutes, and at every 5 minutes
after that for total of 2-3 hr). A small region of interest (~2m) of the mitochondria was
activated in the third time-frame using 405 nm laser at two middle planes of 3-D
acquisition. The fluorescence intensity was measured using Slidebook (Intelligent
Imaging Innovations-3i). The maximum intensity projections (MIP) of the z-stacks for
each time point were created. The activated mitochondria were masked by thresholding
the pixel intensities above the background. The total area of intensity (all pixels above
threshold) was normalized to the post-activation time point and plotted over time.
Analysis of Mitochondrial Morphology and Shape
Cells were grown in 4-well chambers and were transiently transfected using
Fugene6 with mito-DsRed (Clontech). Images were captured using a Marianas spinning
disk confocal (SDC) imaging system using a 63X 1.4 NA Apochromat objective (Zeiss).
Images were acquired from the top to the bottom of the mitochondria in 0.4m zsections. For morphological analysis, the fluorescence intensity was measured using
Slidebook. A Laplacian 2-D spatial filter was applied to the MIP to highlight
mitochondrial structures and an intensity threshold was applied to the images to mask
mitochondrial objects. A shape factor consisting of p2/4A (p=perimeter and A=area)
was applied to all the mitochondrial objects in each cell type (Koopman et al., 2005).
Mitochondrial DNA Isolation and Quantification
Total cellular DNA was extracted using the DNeasy kit (Qiagen). The amount of
mtDNA present per nuclear genome was determined by quantitative real-time PCR using
the following primer pairs: mtDNA forward primer, cctatcacccttgccatcat; mtDNA reverse
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primer, gaggctgttgcttgtgtgac. To quantify nuclear DNA we used primers for the Pecam
gene on chromosome 6 Nuclear DNA forward primer, atggaaagcctgccatcatg;
Nuclear DNA reverse primer, tccttgttgttcagcatcac. Quantification of relative copy number
differences was carried out by analyzing the difference in threshold amplification
between mtDNA and nuclear DNA (delta delta C(t) method).
Mitochondrial Membrane Potential and Image Analysis
Cells were stained in dark with 10 nM tetramethylrhodamine (TMRM)
(Invitrogen) in Hank’s balanced salt solution (HBSS, Gibco) at 37°C for 20 minutes.
Images were captured on a Marianas spinning disk confocal (SDC) imaging system using
a 63X 1.4 NA Apochromat objective (Zeiss). Imaging conditions (laser excitation power
at 561 nm, exposure time and camera gain) were identical for all samples. Mean pixel
intensity values of all mitochondria in the image (representative of mitochondrial
potential) were obtained by masking the signal with Ridler-Calvard automatic
thresholding algorithm implemented in Slidebook 5.0 (3i).
Transmission Electron Microscopy
Wild-type and Mcl-1-deficient MEFs and Mcl-1-deleted livers were fixed in 2.5%
gluteraldehyde in 0.1M sodium cacodylate buffer and post fixed in 2% osmium tetroxide
in 0.1M sodium cacodylate buffer with 0.3% potassium ferrocyanide for 2 hours. Tissue
was enblocked stained with 4% aqueous uranyl acetate for 1 hour then dehydrated
through a series of graded ethanol to propylene oxide, infiltrated and embedded in epoxy
resin and polymerized at 70C overnight. Semi-thin sections (0.5 m) were stained with
toluidine blue for light microscope examination. Ultra-thin sections (80 nm) were cut and
imaged using a JEOL 1200 electron microscope with an AMT XR 111 camera.
Immuno-electron Microscopy
Mitochondria were isolated from pI-pC-treated wt or Mcl-1f/f plus Mx1-Cre liver.
Mitochondrial fractions were fixed for 2 hours using a 4% Paraformaldehyde in 0.1M
Phosphate Buffer. The fractions were then embedding in a 12% gelatin and then
immersed in 2.3M sucrose overnight. They were frozen using liquid nitrogen and were
then cryo-sectioned at a thickness of 85 nm and a temperature of -110°C using a Leica
UCT ultramicrotome. The cryo-sections were placed on formvar coated nickel grids and
labeled with anti-MCL-1 primary antibody (Abcam) and protein A gold secondary (Cell
Microscopy Center) as described previously (Peters et al., 2006). Briefly, Data
Acquisition was carried out utilizing a JEOL 1200 EX II electron microscope equipped
with an 11 megapixel AMT camera.
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Immunofluorescence
Mcl-1-deficient MEFs were grown in 4-well chamber slides and transfected using
Fugene6 with Mcl-1 constructs. Cells were treated with Mitotracker red (Invitrogen) for
45 minutes at 37C. Cells were fixed in 4% paraformaldehyde and immunostained with
anti-MCL-1 (Rockland) and Alexa488 anti-rabbit IgG (Invitrogen). Images were
collected using Leica DM IRBE microscope equipped with a Leica TCS Confocal
System using a 63X magnification.
Enzymatic Activity of Electron Transport Chain Components
For all the enzymatic assays mitochondria were isolated from pI-pC-treated wt or
Mcl-1f/f plus Mx1-Cre liver (Opferman et al., 2005). The activity of NADH-ubiquinone
oxidoreductase (complex I) was assayed as previously described (Frost et al., 2005).
Briefly, mitochondria were lysed with dodecyl maltoside in a phosphate buffer (pH 7.4)
containing MgCl2 and NADH. The reaction was started by the addition of CoQ1, upon
which NADH oxidation was followed at 340 nm for several minutes. Changes in
absorbance prior to the addition CoQ1 were recorded as a blank. Activity was calculated
using the extinction coefficient 6.22 mM-1cm-1 for NADH. Succinate-ubiquinone
oxidoreductase (complex II) activity was assayed by measuring the succinate dependent
reduction in DCIP, mediated by CoQ1. The reaction was followed by recording
absorbance at 600 nm following the addition of succinate (Miyadera et al., 2003).
Succinate-independent absorbance changes were measured as a blank. Activity was
calculated using the extinction coefficient of 21 mM-1cm-1 for DCIP. Cytochrome c
oxidase activity (complex IV) was assayed by measuring the oxidation of cytochrome c
at 550 nm and calculated using the extinction coefficient of 19.6 mM-1cm-1as previously
described (Miro et al., 1998). Pyruvate dehydrogenase (PDH) activity was assayed by
measuring the pyruvate-dependent reduction of INT, mediated by PMS, as previously
described (Hinman and Blass, 1981). Briefly, mitochondria lysed with dodecyl maltoside
were incubated in a Tris (pH 7.4) buffer containing NAD+, TPP, CoA, MgCl2, BSA,
PMS, and pyruvate. Absorbance changes at 500 nm were recorded and activity was
calculated using the absorption coefficient 12.4 mM-1cm-1. Identical samples lacking
either mitochondria or pyruvate were prepared as blanks.
Isolation of Respiratory Complexes and Supercomplexes
Mitochondria were isolated from pI-pC-treated wt or Mcl-1f/f plus Mx1-Cre liver.
Mitochondrial isolation was carried out as described previously (Fernandez-Vizarra et al.,
2002). Isolation of the complexes and supercomplexes was completed as previously
described (Acin-Perez et al., 2008).
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Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE)
Mitochondrial membrane proteins (20 g) were loaded and run on 3-12% firstdimension (1D) gradient BN-PAGE gel was as described earlier (Acin-Perez et al.,
2008). The 1D gel was transferred onto PVDF and immunoblotted with indicated
antibodies.
 -Phosphatase Treatment
Wild-type MEFs were treated with DMSO or 10μM MG-132 for 4 hours after
which the cells were lysed in 10mM Tris-HCl, pH 7.5, 150mM NaCl, 1mM EDTA, 1%
NP-40, 1mM DTT, 1mM PMSF containing protease inhibitors on ice for 30 minutes.
Lysates were incubated with or without -protein phosphatase (New England Biolabs) for
              -MCL-1
(Rockland), anti-Phospho-AKT(Ser473) (Cell Signaling), anti-AKT (Cell Signaling) and
anti-Actin (Millipore).
Edman Sequencing of MCL-1
MCL-1 protein was immunoprecipitated from transiently-transfected 293T cells
using FLAG Lysis Buffer (30 mg of input), resolved by SDS-PAGE, and transferred to
PVDF membrane. Coomassie-stained membrane was excised and submitted to the W.M.
Keck Foundation Biotechnology Resource Laboratory at Yale University and subjected
to 8 rounds of N-terminal sequencing.
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CHAPTER 3.

RESULTS*

Mcl-1-deletion Results in Mitochondrial Morphology Defects
SV40-transformed wild-type (wt) or Mcl-1f/f Rosa-ERCreT2 murine embryonic
fibroblasts (MEFs) in which endogenous Mcl-1 can be deleted by tamoxifen-mediated
induction of the Cre-recombinase were generated (hereafter referred to as Mcl-1-deletion)
(Fig. 3.1a). Inducible Mcl-1-deletion in MEFs did not trigger spontaneous apoptosis
(Fig. 3.1b), but resulted in defective proliferation (Fig. 3.1c). Notably, Mcl-1-deletion
induced the appearance of punctate mitochondria and the loss of the normal tubular
mitochondrial network that was present in control cells (Fig. 3.2a, b). Furthermore,
ultrastructural defects including defective cristae harboring balloon-like, vesicular
structures were readily apparent within the majority of mitochondria in Mcl-1-deficient
MEFs (Fig. 3.2c, d). These abnormal cristae morphologies were not limited to
transformed MEFs as similar defects were observed in primary Mcl-1-deleted liver
mitochondria (Fig. 3.3a). Proteins involved in oxidative phosphorylation are enriched in
the inner mitochondrial membranes (IMM) that make up the cristae (Gilkerson et al.,
2003; Vogel et al., 2006); therefore, we assessed whether Mcl-1-deletion altered the
enzymatic activity of the respiratory chain complexes. Mcl-1-deletion in mouse liver
mitochondria significantly decreased the ability of NADH dehydrogenase (complex I),
succinate dehydrogenase (complex II), and cytochrome c oxidase (complex IV) to
transfer electrons; whereas pyruvate dehydrogenase (PDH) activity was unchanged (Fig.
3.3b). Deletion of Mcl-1 in transformed MEFs did not result in massive apoptosis,
probably because MEFs do not express high levels of BH3 proteins; thus, are not
“primed” for death. However, the small amount of apoptosis observed may be enough to
cause a change in proliferation since cell growth is logarithmic and cell death is not. Loss
of MCL-1 expression in MEFs and hepatocytes did result in dysregulation of the normal
reticular mitochondrial network, cristae morphological abnormalities, and defects in
electron transport chain enzymatic function.
MCL-1 Localizes to Two Distinct Mitochondrial Sub-compartments
To understand the mechanisms underlying the dependence on MCL-1 for normal
cristae morphology, we investigated the localization of MCL-1 within mitochondria. By
immunoblot analysis MCL-1 appeared as a doublet or triplet in percoll-purified liver
mitochondria devoid of contaminating endoplasmic reticulum (ER) (Fig. 3.4a). MCL-1
is a phosphorylated protein (Domina et al., 2004; Maurer et al., 2006; Morel et al., 2009);
however, phosphatase-treatment of cell lysates did not abolish the 40 kD species
*
Reprinted with permission. Perciavalle, R.M., Stewart, D.P., Koss, B., Lynch, J.,
Milasta, S., Bathina, M., Temirov, J., Cleland, M.M., Pelletier, S., Schuetz, J.D., et al.
(2012). Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples
mitochondrial fusion to respiration. Nature Cell Biology 14, 575-583.
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Figure 3.1. Inducible Mcl-1-deletion in MEFs Does Not Affect the Cell Viability.
(a) Mcl-1f/f Rosa-ERCreT2 or wild-type (wt) Rosa-ERCreT2 MEFs (control MEFs) were
treated with tamoxifen or DMSO for indicated times to induce deletion of endogenous
Mcl-1 then immunoblotted for MCL-1 or Actin (loading control). (b) Mcl-1f/f RosaERCreT2 or wt control MEFs were treated with tamoxifen or DMSO (vehicle control) for
indicated times, to induce deletion of endogenous Mcl-1, and assessed for cell death.
Annexin-V and PI double-negative cells were scored as viable. Bars represent the
average of 3 independent experiments and the error bars denote the SEM. (c) Mcl-1f/f
Rosa-ERCreT2 or wt Rosa-ERCreT2 MEFS were treated with tamoxifen (48 hours),
seeded, and counted by hemocytometer at the indicated times. The data represent
averages and SEM of 3 independent experiments.
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Figure 3.2. Inducible Mcl-1-deletion in MEFS Results in Mitochondrial
Morphology Defects.
(a) Mcl-1f/f Rosa-ERCreT2 or wt Rosa-ERCreT2 MEFs expressing matrix-targeted
DsRed fluorescent protein were treated with DMSO or tamoxifen for 96 hours to induce
deletion of endogenous Mcl-1, then imaged to detect mitochondrial morphology. Scale
bars represent 10m. (b) Average shape factor of mitochondrial matrix for Mcl-1f/f RosaERCreT2 or control MEFs 96 hours after deletion. A shape factor of 1.0 indicates
circular mitochondria and the higher the number, the more reticular the network. A shape
factor consisting of p2/4A (p=perimeter and A=area) was applied to all the
mitochondrial objects in each cell type (Koopman et al., 2005). Error bars represent the
standard error of the mean (SEM) from 10 imaged cells (~3000 mitochondria) and
statistical significance was determined by unpaired t-test (*p<0.01). (c) Transmission
electron micrographs of wt or Mcl-1-deficient MEFs. Scale bars represent 500 nm. (d)
Quantification of mitochondrial cristae morphology from wt or Mcl-1-deficient MEFs.
Mitochondria were counted from ~100 individual cells and scored for normal (lamellar)
or ballooned and swollen cristae (disorganized). Error bars indicated the SEM from 3
independent experiments.
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Figure 3.3. Mcl-1-deletion Induces Mitochondrial Abnormalities.
(a) Transmission electron micrographs of pI-pC-treated Mcl-1f/f Mx1-Cre mouse liver 14
days after pI-pC treatment. Size bars represent 500 nm. (b) Enzymatic assays for
indicated electron transport chain components and pyruvate dehydrogenase (PDH) from
mouse liver mitochondria prepared from Mcl-1f/f Mx1-Cre or wt Mx1-Cre (wt) mice 14
days after treatment with pI-pC. Three independent animals were assayed in triplicate
(n=9) and error bars indicated the SEM. Statistical significance was determined by
unpaired t-test (*p<0.01).
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Figure 3.4. Origin of MCL-1 Protein Species.
(a) Crude or Percoll-purified mouse liver mitochondria were western blotted for
expression of MCL-1, Protein Disulphide Isomerase (PDI, endoplasmic reticulum, ER),
or cytochrome c (inner membrane space, IMS). (b) Wild-type (wt) MEFs were either
treated with or without proteasome inhibitor (MG-132), then cell lysates were incubated
in the absence or presence of -protein phosphatase. Lysates were immunoblotted with
anti-MCL-1, anti-Phospho-AKT (Ser473), anti-AKT, and Actin for loading control. (c)
Lysates from wt MEFs or Mcl-1-deleted stably-expressing vector, wild-type Mcl-1, or
Mcl-1 in which its ATG start codon was mutated to TAG (Mcl-1ATG) were
immunoblotted using anti-MCL-1 and anti-Actin for loading control. (d) Lysates from
Mcl-1-deleted or wt MEFs stably-expressing vector, wild-type Mcl-1, or Mcl-1 in which
the putative cryptic splice donor/acceptor pair (nucleotide: 52 G to A and 189 G to T)
was mutated (Mcl-1SD;SAmut) were immunoblotted using anti-MCL-1 and anti-Actin
(loading control).
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indicating its slower migration is not due to differential phosphorylation (Fig. 3.4b). It
has been proposed that non-canonical translational initiation at a non-ATG leads to the
production a faster-migrating 36 kD truncated protein (Warr and Shore, 2008); however,
removal of MCL-1's start codon did not produce a 36 kD protein, instead it produced a 31
kD truncated-protein from a downstream ATG codon (Fig. 3.4c). It has also been
proposed that non-canonical mRNA splicing generates the 36 kD species (Kojima et al.,
2010); however, ablation of the putative splice donor and acceptor pairs still produced the
doublet in cells (Fig. 3.4d). Thus, proteolytic cleavage appears to be the most likely
contributor to generate the faster migrating 36 kD species (De Biasio et al., 2007; Huang
and Yang-Yen, 2010). Indeed, amino-terminal Edman sequencing of
immunoprecipitated MCL-1 detected two amino-terminal cleavage sites: the first
between MCL-1's isoleucine-10 and glycine-11 and another between leucine-33 and
valine-34. Consequently, proteolysis of MCL-1's amino-terminus gives rise to three
different molecular weight MCL-1 species: full-length (40 kD), cleaved at isoleucine-10
(38 kD), and cleaved at leucine-33 (36 kD).
Unexpectedly, the variant forms of MCL-1 exhibited different mitochondrial sublocalization; the slowly migrating bands of MCL-1 (40 kD and 38 kD) were enriched in
the OMM, while the faster migrating form (36 kD) was only detected in the mitoplast
fraction, consisting mainly of IMM and matrix (Fig. 3.5a). Indeed, while both the 40 kD
and 36 kD forms of MCL-1 were tightly associated with disrupted and alkali-washed
mitochondrial membranes, only the 38 kD species exhibited a looser association with
membranes (Fig. 3.5b). Furthermore, when mitochondria isolated from MEFs were
treated with proteinase K, the 40 kD and 38 kD forms of MCL-1 were sensitive to
protease digestion, but the 36 kD species remained resistant to degradation even after
osmotic shock-mediated permeabilization of the OMM (Fig. 3.5c). Moreover,
mitochondria from mouse liver and human non-small cell lung cancer cell lines exhibited
the same protease sensitivity, suggesting that the sub-mitochondrial localization of MCL1 is conserved in both primary murine tissues and human cell lines (Fig. 3.5d, e).
Immunoelectron microscopy of isolated liver mitochondria also indicated that
endogenous MCL-1 localized to both the OMM and IMM (Fig. 3.6). Together, these
results indicate that the 40 kD and 38 kD forms of MCL-1 reside on the outer leaflet of
the OMM, whereas the 36 kD form is associated with the inner membrane and is
confined within the mitochondrial matrix.
During mitochondrial protein import, nuclear encoded proteins are processed by
importation machinery consisting of the translocases of outer membrane (TOM) and
inner membrane (TIM) proteins (Schmidt et al., 2010). RNAi-mediated gene silencing of
either TOM40 or TIM50 prevented MCL-1's mitochondrial import rendering it
completely protease sensitive (Fig. 3.7). Accordingly, MCL-1 undergoes TOM- and
TIM-dependent mitochondrial import.
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Figure 3.5. MCL-1 Resides in Different Sub-mitochondrial Localizations.
(a) Mouse liver mitochondria (HM) were sub-fractionated into outer mitochondrial
membrane or mitoplast and western blotted for MCL-1, BCL-XL (outer mitochondrial
membrane, OMM), Prohibitin1 (inner mitochondrial membrane, IMM), or MnSOD
(matrix). (b) Mouse liver mitochondria (HM) were swollen and sonicated to disrupt
membranes, washed with alkali buffer (pH 11.5) to detach loosely-associated proteins
from membranes, and then re-isolated by ultra-centrifugation. Supernatant (Supe) and
membrane fractions (Pellet) were western blotted for MCL-1, Prohibitin1, or MnSOD.
(c, d, & e) Mitochondria isolated from (c) wt MEFs, (d) wt mouse liver, or (e) human
Non-Cell Lung Cancer (NSCLC) cells were subjected to proteinase K (PK) proteolysis to
digest exposed proteins, osmotic shock (OS) was used to disrupt the outer mitochondrial
membrane, and detergent (SDS) was used to disrupt both inner and outer mitochondrial
membranes. Lysates were resolved and subjected to immunoblot analyses.
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Figure 3.6. MCL-1 Is Localized to Both the Outer and Inner Mitochondrial
Membranes.
Mouse liver mitochondria from Mcl-1f/f Mx1-Cre (Mcl-1-deleted) or wt Mx1-Cre (wt)
mice 14 days after treatment with pI-pC were fixed 4% paraformaldehyde in 0.1 M
Phosphate Buffer and subjected to immuno-electron microscopy. Magnification is
20,000X and scale bar represents 100 nm.
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Figure 3.7. MCL-1 Undergoes TIM/TOM Mitochondrial Import.
Mitochondria isolated from wt MEFs transfected with control or siRNA-oligos specific to
TOM40 or TIM50 were subjected to protease treatment as described in Fig. 3.5.

33

MCL-1 Possesses a Mitochondrial Targeting Sequence
MCL-1 shares sequence homology to BCL-2 in its carboxy-terminal region;
however, its amino-terminus is poorly conserved (Kozopas et al., 1993). To define the
domains necessary for appropriate localization to mitochondria, MCL-1 mutants were
generated (Fig. 3.8a). Both MCL-1's amino- and carboxy-terminal domains were
necessary for its proper mitochondrial localization and generation of a doublet by
immunoblot analysis (Fig. 3.8b, c). Proteins imported into the mitochondrial matrix often
contain mitochondrial targeting sequences (MTS) (Schmidt et al., 2010). To determine if
the amino-terminus on MCL-1 contains a MTS, the first 50 amino-terminal amino acids
of MCL-1 were fused to the amino-terminus of human BCL-2 (hBCL-2). Human BCL-2
is normally restricted to the OMM; however, the chimeric protein formed a doublet of
which the faster migrating species appeared in the matrix, thus validating that MCL-1's
amino-terminus possesses an MTS (Fig. 3.8d). Imported mitochondrial proteins often
possess MTS's containing charged residues (Schmidt et al., 2010). Mutagenesis of the
arginine residues at MCL-1's positions 5 and 6 to alanine (hereafter called MCL-1OM)
maintained its localization to mitochondria, but abrogated the formation of MCL-1's 36
kD form (Fig. 3.9a, b, c). Notably, MCL-1OM was completely sensitive to proteolysis
indicating that the mutagenesis blocks mitochondrial import (Fig. 3.9d). To generate a
MCL-1 mutant that resides solely within the mitochondrial matrix, we used the
mitochondrial targeting sequence of matrix-localized ATP-synthase (Pfanner et al., 1987)
and fused it to amino-truncated MCL-1 (hereafter called MCL-1Matrix) (Fig. 3.9a). MCL1Matrix localized to mitochondria, and only produced a single protein species (Fig. 3.9b,
c). Moreover, MCL-1Matrix was completely resistant to protease attack even under
conditions of osmotic shock illustrating that it localizes to the matrix (Fig. 3.9d).
Inhibition of Cell Death Requires Outer Membrane-localized MCL-1
Given that MCL-1 antagonizes cell death, we assessed the anti-apoptotic activities
of the different mitochondrial localized mutants of MCL-1. Similar levels of wt MCL-1,
MCL-1OM, or MCL-1Matrix were stably expressed in Mcl-1f/f Rosa-ERCreT2 MEFs (Fig.
3.10a). Mcl-1-deletion in MEFs did not induce spontaneous apoptosis (Fig. 3.1 b), but
rendered them highly susceptible to cell death stimuli (Fig. 3.10b, c). Expression of
either wt MCL-1 or MCL-1OM protected the MEFs from apoptosis; however, MCL-1Matrix
expressing MEFs were completely sensitive to cell death (Fig. 3.10b, c). Furthermore,
the expression of hBCL-2 in the Mcl-1-deleted MEFs rendered cells substantially more
resistant to death stimuli (Fig. 3.10b, c). MCL-1 binds and sequesters pro-apoptotic
BH3-only molecules, such as BIM, preventing OMM permeabilization and activation of
the downstream apoptotic cascade (Opferman et al., 2003). Both the 40 kD species of wt
MCL-1 and MCL-1OM co-immunoprecipitated with pro-apoptotic BIM; however, no
interaction was detectable between BIM and the 36 kD species of wt MCL-1 or between
BIM and MCL-1Matrix (Fig. 3.10d). Thus, MCL-1OM can bind pro-apoptotic modulators
and prevent cell death similarly to wt MCL-1, but MCL-1Matrix cannot sequester proapoptotic modulators or prevent apoptosis.
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Figure 3.8. Both the Amino (N)- and Carboxy (C)-termini Are Required for
Proper Mitochondrial Localization of MCL-1.
(a) Schematic illustration of MCL-1 deletion mutants. Yellow boxes indicate BCL-2
homology (BH) domains and the red box indicates the C-terminal hydrophobic domain.
(b) Confocal immunofluorescence of Mcl-1-deficient MEFs transiently-expressing
indicated Mcl-1 constructs were fixed and stained for MCL-1 (green), mitochondria
(Mitotracker, in red), and nucleus (DAPI, in blue). Co-localization of green and red
channels is shown in yellow overlay. Size bars represent 10m. (c) Whole cell lysates
(WCL), isolated heavy membranes (HM) enriched for mitochondria or cytosolic (cyto)
sub-cellular fractions were isolated from Mcl-1-deleted MEFs stably-expressing indicated
MCL-1 constructs. Fractions were western blotted for MCL-1, BAX (cytosolic marker)
or MnSOD (mitochondrial marker). (d) Mitochondria from Mcl-1-deficient MEFs stablyexpressing human BCL-2 (hBCL-2) or a chimeric fusion of the first 50 amino acids of
MCL-1 to hBCL-2 (mMCL-150-hBCL-2) were subjected to protease treatment as
described in Fig. 3.5. Both the fusion protein and hBCL-2 were detected with antihBCL-2 antibody.
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Figure 3.9. MCL-1 Mutants Restrict Mitochondrial Localization.
(a) Schematic illustration of MCL-1 mutants. Yellow boxes indicate BCL-2 homology
(BH) domains and the red box indicates the carboxy (C)-terminal hydrophobic domain.
Point mutations are indicated with the original amino acid, site-position and mutated
residue. N. crassa ATP-synthase MTS is indicated in green. (b) Confocal
immunofluorescence of Mcl-1-deficient MEFs transiently expressing indicated Mcl-1
constructs were fixed and stained for MCL-1 (green), mitochondria (Mitotracker, in red),
and nucleus (DAPI, in blue). Co-localization of green and red channels is shown in
yellow overlay. Scale bars represent 10m. (c) Mitochondria enriched, heavy membrane
(HM) or cytosol (cyto) sub-cellular fractions were isolated from Mcl-1-deficient MEFs
stably-expressing indicated constructs. Whole cell lysates (WCL) were run as a control.
Fractions were resolved and western blotted for MCL-1, BAX (cytosol) or MnSOD
(matrix). (d) Mitochondria from Mcl-1-deficient MEFs stably-expressing indicated
constructs were subjected to protease treatment as described in Fig. 3.5.
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Figure 3.10. Anti-apoptotic Activity of MCL-1 Requires Localization to the Outer
Mitochondrial Membrane.
(a) Mcl-1f/f Rosa-ERCreT2 MEFs stably-expressing indicated constructs were treated for
48 hours with tamoxifen to induce deletion of endogenous Mcl-1 then western blotted for
MCL-1, hBCL-2, or Actin (loading control). Vector-expressing, tamoxifen-treated wt
Rosa-ERCreT2 MEFs (lane 1) serve as control. (b & c) Rosa-ERCreT2 MEFs stablyexpressing indicated constructs were treated for 96 hours with tamoxifen to induce
deletion of endogenous Mcl-1 and were administered indicated doses of (b) staurosporine
for 16 hours or (c) etoposide for 24 hours after which cell death was determined.
Annexin-V and PI double-negative cells were scored as viable. Bars represent the
average of 3 independent experiments and the error bars denote the SEM. Vectorexpressing, tamoxifen-treated wt Rosa-ERCreT2 MEFs serve as control. (d) Lysates
were immunoprecipitated with anti-BIM or anti-rat IgG antibody and immune complexes
were resolved and immunoblotted for MCL-1 and hBCL-2. Endogenous murine BCL-2
(mBCL-2) serves as a control for equal BIM immunoprecipitation. 1/10th input of
immunoprecipitation is depicted. Post-immunoprecipitated supernatants (Unbound Flow
Through) indicate non-precipitated proteins remaining in lysate.
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MCL-1 Matrix-localized MCL-1 Is Required for Normal IMM Structure and
Efficient Mitochondrial Fusion
Since Mcl-1-deletion resulted in ultrastructural abnormalities in both primary and
transformed cells (Fig. 3.2c, d & Fig. 3.3a) we investigated whether reintroduction of
MCL-1Matrix can rescue the abnormal IMM structure. Expression of either wt MCL-1 or
MCL-1Matrix largely restored normal IMM structure whereas MCL-1OM did not (Fig.
3.11a, b). Because mitochondrial structure is regulated by the opposing processes of
fission and fusion (Chen et al., 2010) and Mcl-1-deleted cells had fragmented
mitochondria (Fig. 3.2a, b), we asked which form of MCL-1 is required for normal
matrix fusion. Accordingly, we used photo-activatable-GFP targeted to the
mitochondrial matrix (Karbowski et al., 2004). Upon Mcl-1-deletion, there was a
significant delay in mitochondrial fusion that could be corrected by expression of either
wt MCL-1 or MCL-1Matrix but not by MCL-1OM or hBCL-2 (Fig. 3.11c, d). Furthermore,
expression of human MCL-1 could ameliorate the delay in fusion and functionally
compensated for loss of mouse MCL-1 implying this function is evolutionarily conserved
(Fig. 3.12). Therefore, matrix-localized MCL-1 is necessary to promote normal IMM
structure, efficient mitochondrial fusion and maintenance of the mitochondrial reticular
network.
Normal Mitochondrial Bioenergetics Requires Matrix-localized MCL-1
Whereas the structure of the IMM is intricately linked to the metabolic status of the
mitochondria (Vogel et al., 2006) and defects in mitochondrial morphology are
associated with respiratory dysfunction (Chen et al., 2010), we examined the role of
MCL-1Matrix in promoting efficient ATP generation and oxidative phosphorylation.
Transformed MEFs generate energy predominantly by glycolysis rather than by oxidative
phosphorylation, therefore to stimulate mitochondrial respiration they were cultured in
glucose-free media supplemented with galactose (Reitzer et al., 1979; Rossignol et al.,
2004). Under these conditions, Mcl-1-deletion significantly reduced ATP levels, but
expression of either wt MCL-1 or MCL-1Matrix restored normal ATP levels (Fig. 3.13a).
In contrast, expression of either MCL-1OM or hBCL-2 in the Mcl-1-deleted MEFs did not
rescue ATP levels, suggesting that merely restoring anti-apoptotic function is insufficient
to promote normal energy production (Fig. 3.13a). Since the proton gradient across the
IMM drives ATP synthesis, we assessed whether the mitochondrial membrane potential
was altered in cells lacking MCL-1. Indeed, Mcl-1-deletion decreased mitochondrial
membrane potential, which was improved by stable expression of either wt MCL-1 or
MCL-1Matrix, but not MCL-1OM (Fig. 3.13b, c). When grown in galactose-media, Mcl-1deleted MEFs also exhibited slower proliferation compared to control cells (Fig. 3.13d).
Expression of either wt MCL-1 or MCL-1Matrix corrected the proliferative defect, whereas
MCL-1OM or hBCL-2 expression was unable to compensate for endogenous Mcl-1deletion (Fig. 3.13d). This suggests that the proliferative defect is not due to a small
amount of apoptosis since MCL-1Matrix does not reatain anti-apoptotic activity but
proliferates faster than MCL-1OM. Consequently, MEFs lacking matrix-localized MCL-1
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Figure 3.11. Lacking Matrix-localized MCL-1 Results in Mitochondrial IMM
Structure and Fusion Defects.
(a) Transmission electron micrographs (12,000X) of Mcl-1f/f Rosa-ERCreT2 MEFs
stably-expressing indicated constructs were treated with tamoxifen to induce deletion of
endogenous Mcl-l. Scale bars represent 500 nm. (b) Quantification of mitochondrial
cristae morphology from Mcl-1f/f Rosa-ERCreT2 MEFs stably-expressing indicated
constructs that were treated with tamoxifen to induce deletion of endogenous Mcl-1.
Mitochondria were cunted from ~100 individual cells and scored for normal (lamellar) or
ballooned and swollen cristae (disorganized). Error bars indicated the SEM from 3
independent experiments. (c) Mitochondrial fusion was measured 96 hours after Mcl-1deletion in Mcl-1f/f Rosa-ERCreT2 MEFs stably-expressing indicated constructs. Cells
were transiently-transfected with photoactivatable-GFP (PA-GFP) targeted to the
mitochondrial matrix. Depicted are representative images from 2, 30, and 60 minutes
after PA-GFP activation. Scale bars represent 10m. (d) Quantitation of the rate of
mitochondrial fusion measured 96 hours after Mcl-1-deletion as the ratio of remaining
activated mitochondrial area. Data represent average and SEM of fluorescence area over
time of 3 independent experiments (n=16 cells). As mitochondria fuse, the PA-GFP
signal dilutes decreasing intensity of signal in the area of activation.
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Figure 3.12. Human MCL-1 Rescues Mitochondrial Fusion Defect.
Mitochondrial fusion was measured 96 hours after Mcl-1-deletion in Mcl-1f/f RosaERCreT2 MEFs stably-expressing indicated constructs. Cells were transiently-transfected
with photoactivatable-GFP (PA-GFP) targeted to the mitochondrial matrix.
Quantification rate of mitochondrial fusion is indicated as a ratio of remaining activated
mitochondrial area. Data represent average and SEM of fluorescence area over time of 3
independent experiments (n=16 cells).
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Figure 3.13. Matrix-localized MCL-1 Is Required for Efficient Bioenergetics and
Proliferation.
(a) Mcl-1f/f Rosa-ERCreT2 MEFs stably-expressing indicated constructs were grown in
glucose-free media containing galactose and treated for 96 hours with tamoxifen to
induce deletion of endogenous Mcl-1 and total cellular ATP was evaluated in galactose
media. Vector-expressing, tamoxifen-treated wt Rosa-ERCreT2 MEFs serve as positive
control. Data represent the averages of 3 independent experiments and the error bars
denote the SEM. Statistical significance was determined by unpaired t-test (*p<0.01).
(b) Quantification of mitochondrial membrane potential from Mcl-1f/f Rosa-ERCreT2
MEFs, stably-expressing indicated constructs, were treated for 96 hours with tamoxifen
to induce deletion of endogenous Mcl-1 and stained with 10 nM TMRM and imaged.
Data represent average mean fluorescence intensities and SEM from 20 cells. (c) Mcl-1f/f
Rosa-ERCreT2 MEFs stably-expressing indicated constructs that were treated for 96
hours with tamoxifen to induce deletion of endogenous Mcl-1 and were stained with 20
nM TMRM and imaged for mitochondrial membrane potential. (d) Mcl-1f/f RosaERCreT2 MEFS stably-expressing indicated constructs were grown in glucose-free
media containing galactose and were treated with tamoxifen (48 hours), seeded in
glucose-free media containing galactose, and counted by hemocytometer at the indicated
times. Vector-expressing, tamoxifen-treated wt Rosa-ERCreT2 MEFs serve as a control.
The data represent averages and SEM of 3 independent experiments. Statistical
significance of control versus Mcl-1-deleted and MCL-1OM versus MCL-1Matrix were
determined by unpaired t-test (p<0.001).
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generate less energy, have decreased mitochondrial membrane potential, and grow poorly
in galactose-media even in the presence of anti-apoptotic MCL-1 on the OMM.
Respiratory complexes pass electrons through the electron transport chain
components to reduce molecular oxygen, thus generating a proton gradient that drives
ATP production by the F1F0-ATP synthase (Wallace, 1999). Since both mitochondrial
membrane potential and ATP production were decreased in Mcl-1-deleted MEFs (Fig.
3.13a, b, c) we determined if respiration was altered by measuring oxygen consumption
rates (OCR) using the Seahorse XF24 analyzer (Ferrick et al., 2008). Mcl-1-deletion
decreased basal OCR by ~50% compared to non-deleted MEFs (Fig. 3.14a). Expression
of either wt MCL-1 or MCL-1Matrix fully restored basal OCR; whereas neither MCL-1OM
nor hBCL-2 expression could restore normal basal OCR (Fig. 3.14a). To induce
maximal OCR, a proton ionophore, FCCP, was added in order to dissipate the proton
gradient, thereby activating maximum respiration (Nicholls, 1974). Strikingly, Mcl-1deleted MEFs were incapable of increasing their OCR above basal rates when treated
with FCCP (Fig. 3.14b); however, maximal OCR was completely restored by expression
of either wt MCL-1 or MCL-1Matrix, but not by MCL-1OM or hBCL-2 (Fig. 3.14b).
Collectively, matrix-localized MCL-1 is required for optimal oxidative phosphorylation
in cells, a function that is acutely separate from its anti-apoptotic role at the OMM.
Elevations in mitochondrial reactive oxygen species (ROS) are common in cells
with mitochondrial dysfunction (Wallace, 1999). Upon Mcl-1-deletion, mitochondrial
superoxide levels were elevated, but expression of either wt MCL-1 or MCL-1Matrix
prevented the increase in mitochondrial superoxide production, consistent with their
ability to rescue normal mitochondrial function (Fig. 3.14c). In contrast, neither hBCL-2
nor MCL-1OM could prevent increased superoxide generation, indicating that merely
restoring anti-apoptotic function is inadequate to prevent superoxide induction (Fig.
3.14c). Hence, expression of the mitochondrial matrix form of MCL-1 is sufficient to
both maintain mitochondrial respiration and prevent potentially dangerous ROS
production in cells.
MCL-1 Is Required for Assembly of F1F0-ATP Synthase Oligomers
The movement of electrons through the respiratory complexes depends on the
structure and assembly of the electron transport chain complexes (Acin-Perez et al.,
2008). Structural and functional evidence has revealed that the individual electron
transport chain complexes (I, II, III, and IV) organize into inter-complex assemblies
known as supercomplexes, which are disrupted in the absence of one of their component
complexes (Acin-Perez et al., 2008). The supramolecular organization of respiratory
complexes is hypothesized to increase the efficiency of electron transport and minimize
ROS production (Acin-Perez et al., 2008; Genova et al., 2008). Mcl-1-deletion did not
affect the total protein expression of nuclear-encoded respiratory chain subunits;
however, the mitochondrial DNA-encoded subunits of complex IV (Cox 1 and Cox 2)
protein levels were decreased (Fig. 3.15a). Therefore, we investigated whether the
decreased Cox 1 and Cox 2 expression may be due to alterations in mitochondrial DNA
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Figure 3.14. Cells Deficient in Matrix-localized MCL-1 Have Defects in Oxygen
Consumption.
(a & b) Oxygen consumption measured 96 hours after Mcl-1-deletion in Mcl-1f/f RosaERCreT2 MEFs stably-expressing indicated constructs under (a) basal and (b) FCCPuncoupled (maximal) respiration. Vector-expressing, tamoxifen-treated wt RosaERCreT2 MEFs serve as positive control. Experiments were performed in triplicate and
the bars represent averages (n=9) and the error bars denote the standard of deviation.
Statistical significance was determined by unpaired t-test (*p<0.01, **p<0.05). (c)
Superoxide was detected by mitoSOX fluorescence 96 hours after Mcl-1-deletion in Mcl1f/f Rosa-ERCreT2 MEFs stably-expressing indicated constructs. Vector-expressing,
tamoxifen-treated wt MEFs serve as a negative control. Average mean fluorescence
intensity (MFI) of 3 independent experiments and error bars indicate the SEM. Statistical
significance was determined by unpaired t-test (*p<0.01).
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Figure 3.15. MCL-1 Is Required for Assembly of Supercomplexes.
(a) Total mouse liver lysates from Mcl-1f/f Mx1-Cre (Mcl-1-deleted) or wt Mx1-Cre (wt)
mice 14 days after treatment with pI-pC were lysed in RIPA and resolved by SDS-PAGE.
Immunoblot were probed to determine expression of Complex I (NDUFA9), Complex II
(Fp70), Complex III (Core 2), Complex IV (Cox I and Cox 2), ATP Synthase subunit F0
B (5F1), ATP Synthase F1 subunit beta (5B), Succinate dehydrogenase, MnSOD, and
MCL-1. Asterix (*) denotes mtDNA-encoded protein (b) Assessment of mtDNA and
nDNA by quantitative real-time PCR. (c & d) Mouse liver mitochondria from Mcl-1f/f
Mx1-Cre (Mcl-1-deleted) or wt Mx1-Cre (wt) mice 14 days after treatment with pI-pC
were lysed in digitonin and resolved by blue native gel polyacrylamide electrophoresis
(BN-PAGE) and blotted to determine native complexes and supercomplexes (SC). (c)
complex I (CI, detected by NDUFA9), complex II (CII, detected by Fp70), complex III
(CIII, detected by Core 2) and complex IV (CIV, detected by Cox I) and (d) ATP
Synthase subunit F0 B (5F1), F1 subunit beta (5B). The native migration of monomers,
dimers, and oligomers are denoted.
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(mtDNA). Indeed, Mcl-1-deletion decreased mtDNA content (Fig. 3.15b). To
investigate the structure of the respiratory complexes and supercomplexes, we used blue
native-polyacrylamide gel electrophoresis (BN-PAGE). Consistent with the loss of the
Cox 1 and Cox 2 subunits of complex IV, Mcl-1-deleted liver mitochondria also
exhibited aberrant assembly of large supercomplexes (composed of complexes I, III, and
IV) as detected by Cox 1 immunoblot (Fig. 3.15c). This is in agreement with the effects
of deletion of complex IV preventing the assembly of large supercomplexes (Acin-Perez
et al., 2008; Diaz et al., 2006). In contrast, the smaller respiratory supercomplexes
appeared relatively unaffected by Mcl-1-deletion (Fig. 3.15c). Therefore, Mcl-1-deletion
results in diminished mtDNA, reduced protein expression of Cox 1 and Cox 2 subunits,
and alterations in the large supercomplexes containing complexes I, III, and IV.
The F1F0-ATP synthase also adopts supramolecular structures including the
constitutive assembly of ATP synthase homo-dimers and higher-order homo-oligomers
(Krause et al., 2005). Furthermore, the assemblage into dimers and oligomers proffered
as a determinant of the mitochondrial cristae structure and suggested to enhance
efficiency of function (Giraud et al., 2002; Gomes et al., 2011; Thomas et al., 2008). As
such, mutations that prevent the oligomerization of ATP synthase result in disorganized
cristae membranes that form concentric circles and onion-like structures (Bornhovd et al.,
2006; Paumard et al., 2002). By BN-PAGE, Mcl-1-deficient liver mitochondria
possessed less oligomeric ATP synthase and exhibited a corresponding increase in the
monomer (Fig. 3.15d). The lack of F1F0-ATP synthase oligomers was not due to loss of
the individual subunits, implying that the defect is in the oligomerization of ATP
synthase (Fig. 3.15a, d). Accordingly, Mcl-1 is required for efficient assembly of F1F0ATP synthase oligomers and in the absence of Mcl-1 there is an increase in the
monomeric form.
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CHAPTER 4.

DISCUSSION

MCL-1 in Normal Cells
MCL-1 is a unique anti-apoptotic BCL-2 family member in that its genetic
ablation results in cell autonomous deficiencies in a myriad of cellular lineages (Arbour
et al., 2008; Dzhagalov et al., 2008; Dzhagalov et al., 2007; Opferman et al., 2005;
Opferman et al., 2003; Rinkenberger et al., 2000; Steimer et al., 2009). However, Mcl-1
gene ablation disables both its anti-apoptotic activity at the OMM as well as its ability to
facilitate mitochondrial function within the matrix. For that reason, it will be important
to determine the relative contributions of MCL-1's different functional roles for
promoting the survival and development of hematopoietic and neuronal lineages. It is
conceivable that both roles of MCL-1 may be critical for normal cell viability. For
example, differentiating cells are subjected to expansion, selection, and homeostatic
regulation often regulated by the access to growth factors in the cellular
microenvironments. As such, MCL-1's critical function during these stages may be to
support cell survival by antagonizing apoptosis. However, it is also possible that during
cellular proliferation and differentiation, metabolic demands on the mitochondria are
modulated. Thus, MCL-1's critical function during such stages may be to facilitate
mitochondrial fitness thereby opposing increased demands for oxidative phosphorylation.
We anticipate that genetic studies separating MCL-1's functional role at the OMM and
matrix will be necessary to delineate the contribution of these roles to normal cellular
development and survival.
MCL-1 in Embryonic Development
Germline ablation of Mcl-l in mice results in an early preimplantation embryonic
lethality at embryonic day 3.5 and, specifically, the embryos have a defective
trophoectoderm (Rinkenberger et al., 2000). Other anti-apoptotic BCL-2 family
members do not display such a severe developmental phenotype, suggesting that MCL-1
plays a unique role during early embryonic development. While apoptosis is extremely
important during development, none of the other apoptotic regulators are required at such
an early embryonic developmental stage (Ranger et al., 2001). Mitochondria have been
shown to play an important role during the preimplantation stage embryo as aerobic
metabolism is the primary source of ATP in the mouse blastocyst (Benos and Balaban,
1983). Furthermore, mitochondria in the trophoectoderm of the blastocyst have a high
inner membrane potential, indicating that these mitochondria are actively respiring,
which is important for early embryonic development (Van Blerkom et al., 2006).
Precisely why Mcl-1 is required for implantation has remained elusive. One possibility is
that MCL-1 facilitates mitochondrial energy production that is required for differentiation
of cytotrophoblasts into the intermediate trophoblast and the syncytiotrophoblast. Failure
of the cytotrophoblasts to differentiate could result in a defective trophoectoderm that is
unable to implant. Another possibility is that MCL-1 is requisite for the mitochondria in
the trophoectoderm to produce enough energy to allow invasion of the placenta. For these
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reasons, it is plausible that MCL-1’s role during embryonic development is not only to
antagonize cell death but is also to promote normal mitochondrial function, assisting in
differentiation and placental invasion of the trophoblast cells that compose the blastoyst.
To determine if the anti-apoptotic or the mitochondrial functions of MCL-1 are important
for early embryonic development, a knock-in gene targeting strategy using MCL-1 OM or
MCL-1Matrix could be used. If neither MCL-1 OM nor MCL-1Matrix is sufficient for
embryonic development then both functions of MCL-1 may be required. In that case, a
polycistronic viral vector can be utilized to co-express both MCL-1 OM and MCL-1Matrix.
MCL-1 in Hematopoiesis
The BCL-2 family members are important regulators of hematopoiesis. While
transgenic expression of BCL-2 in hematopoietic stem cells (HSCs) can increase their
numbers in vivo (Domen et al., 2000), mice that are deficient for Bcl-2 or Bcl-x deficient
ES cells can both still produce hematopoietic cells; however, they exhibit effects later
during specific lineage development (Motoyama et al., 1995; Veis et al., 1993). Instead,
MCL-1 is the key pro-survival molecule during hematopoiesis as inducible deletion of
Mcl-1 results in rapid multi-lineage hematopoietic failure (Opferman et al., 2005). Along
these lines, MCL-1 is unique because it is the essential survival factor for all early
hematopoietic lineages.
The hematopoietic system gives rise to a variety of mature cells including
myeloid and lymphoid lineages. HSCs maintain their populations through a balance of
self-renewal and differentiation and it is unclear how much of a direct role apoptosis has
in the regulation of this balance. In contrast, the more committed lineages, such as
lymphocytes are potently regulated by apoptosis particularly through regulation by
cytokines and growth factors (Opferman, 2007; Opferman and Korsmeyer, 2003).
Evidence has shown that HSCs have a low mitochondrial membrane potential and are
predominantly glycolytic (Simsek et al., 2010). This metabolic phenotype is a
consequence of the hypoxic niche in the bone marrow (Simsek et al., 2010).
Furthermore, long-term hematopoietic stem cells (LT-HSCs), which retain the capacity to
self-renew, are in a quiescent state with a reduced metabolic rate (Wilson et al., 2008). In
contrast, differentiation into the more committed progenitor cells is a high-energy
demand process that requires mitochondrial function (Inoue et al., 2010).
Accordingly, the profound requirement for Mcl-1 in hematopoietic stem cells may
result from a synergy of both the anti-apoptotic and mitochondrial functions. It is
possible that the signals for differentiation and proliferation are coupled such that matrixlocalized and outer membrane-localized MCL-1 cooperate to provide increased energy
upon differentiation into progenitor and antagonize apoptosis to sustain maintenance of
the stem cell pool (Fig. 4.1). Nevertheless, Mcl-1 may have separate roles in distinct
hematopoietic lineages. For example, matrix-localized MCL-1 may be important for
early progenitors where proper mitochondrial function is required for differentiation
whereas anti-apoptotic MCL-1 may be important for survival of the mature cells (Fig.
4.1).
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Figure 4.1. Possible MCL-1 Functions in Normal Homeostasis
In normal stem cells, it is possible that the homeostatic control on self-renewal is
regulated primarily by MCL-1’s OMM anti-apoptotic activity. In contrast, the
proliferation and differentiation of stem cells into progenitors and terminally
differentiated lineages may require efficient energy production promoted by the truncated
MCL-1 targeted to the matrix. Lastly, proper homeostasis of terminally differentiated
cells is likely controlled primarily by MCL-1’s OMM anti-apoptotic activity.
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MCL-1 in the Brain
The requirement of Mcl-1 in the developing nervous system further illustrates the
significance of this pro-survival molecule. In the absence of Mcl-1 widespread apoptosis
occurs in the embryo resulting in embryonic lethality at embryonic day 16 (Arbour et al.,
2008). The development of the cerebral cortex is heavily dependent on apoptosis in order
to select for appropriate cortical neurons before differentiation (Blaschke et al., 1996)
Therefore, MCL-1 may help maintain the balance between proliferation and cell death
during embryonic development of the cerebral cortex. However, in addition to apoptosis,
neurons are extensively dependent on mitochondrial dynamics. The imbalance between
healthy and dysfunctional mitochondria can be a determinant for neurodegenerative
diseases such as Alzheimer’s and Parkinson’s (Chen et al., 2007). Mitochondria are
abundant in synaptic regions since synaptic transmission requires a high ATP demand
(Chan, 2006). It is possible that the different functional roles of MCL-1 at the OMM and
the matrix may have different spatial and temporal requirements for maintaining neuronal
survival and health. For example, during development of the nervous system, while
neurons are being established and eliminated, the anti-apoptotic role of MCL-1 on the
OMM may be the principal function. Anti-apoptotic MCL-1 may be necessary to
maintain the balance between life and death in developing neurons that are controlled by
homeostatic selection processes. In comparison, MCL-1 may have an additional
functional role in adult neurons. Mitochondrial fusion is necessary for mitochondria to
travel long distances from the neuronal cell body to the axonal termini where they
generate ATP, particularly in the motor and sensory neurons that enervate the hands and
feet. In addition to antagonizing cell death, MCL-1 may also promote mitochondrial
fusion in post-mitotic neurons.
Role of MCL-1 in Cancer and Cancer Therapy
MCL-1 is one of the most highly amplified genes in a variety of human cancers
(Beroukhim et al., 2010); therefore, it is imperative to understand the contribution of
MCL-1’s functions to oncogenesis. Furthermore, its expression is often associated with
chemotherapeutic resistance and relapse (Wei et al., 2006; Wuilleme-Toumi et al., 2005).
In many malignancies, MCL-1 appears to be a critical survival molecule. For instance,
MCL-1 is critical for the development and maintenance of acute myeloid leukemia
(Glaser et al., 2012; Xiang et al., 2010). Moreover, MCL-1 overexpression dramatically
accelerates Myc-induced lymphomagenesis (Campbell et al., 2010). Similar to studies in
normal cells, the majority of investigations into the role of Mcl-1 in mouse models of
cancer have genetically ablated both the anti-apoptotic and the mitochondrial functions of
MCL-1 making it difficult to separate the functional contributions of MCL-1’s antiapoptotic and mitochondrial functions.
Oncogenesis can activate tumor suppressor pathways that frequently initiate cell
death pathways. Cancer cells often violate these key cellular checkpoints that would
normally drive the cells to die by programmed cell death. As a result, they often
overcome the apoptotic stress either by reducing the expression of pro-apoptotic factors
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or, more frequently by up regulating anti-apoptotic molecules (Hanahan and Weinberg,
2011). For example, the amplification of Myc is one of the most frequent oncogenic
occurrences observed in human cancers and drives carcinogenesis (Beroukhim et al.,
2010). Oncogenic levels of Myc induce apoptosis that must be overcome in part by overexpression of anti-apoptotic molecules (Bissonnette et al., 1992; Eischen et al., 2001;
Evan et al., 1992; Shi et al., 1992; Zindy et al., 1998). Accordingly, the anti-apoptotic
function of MCL-1 and other anti-apoptotic family members may be obligate in their
promotion of survival as a result of oncogenic stress.
Nevertheless, cancer cells are often rapidly dividing and require increases in
biomass to support abnormal proliferation. Although cancer cells often metabolize
extremely high levels of glucose by glycolysis, glutamine is another essential metabolite
that is excessively consumed through glutaminolysis (Eagle, 1955; Reitzer et al., 1979).
Glutamine is a mitochondrial-oxidizable substrate that is essential for macromolecular
synthesis of nucleic acids, proteins, and lipids required for assembling new cells
(DeBerardinis et al., 2007). In particular, oncogenic Myc has been linked to increased
glutaminolysis through activation of a transcriptional program that renders cancer cells
glutamine dependent (Wise et al., 2008; Yuneva et al., 2007).
Since Mcl-1 is requisite for oncogenesis of Myc leukemia (Xiang et al., 2010) it is
conceivable that both the anti-apoptotic and mitochondrial functions of MCL-1 play an
important role in promoting the survival of Myc-induced cancer. Myc transformation
causes cells to become dependent on anti-apoptotic molecules in order to overcome
apoptotic stress; therefore, the anti-apoptotic activity of MCL-1 may be indispensable.
Nevertheless, it is possible that the non-apoptotic function of MCL-1 may help fulfill the
requirements for rapid cell proliferation in Myc-cancer cells by facilitating the generation
of byproducts from mitochondrial metabolism (DeBerardinis et al., 2007; Deberardinis et
al., 2008).
Cancer Stem Cells and Differentiation Therapy
Normal stem cells undergo self-renewing cell division, which means they
generate daughter cells that have the ability to self-replicate and produce more
differentiated cell lineages (Rossi et al., 2008). Cancer stem cells are defined as cancer
cells that are capable of self-renewal and can give rise to a heterogeneous population of
cancer cells (Vermeulen et al., 2008). For this reason, cancer stem cells can only be
defined experimentally by their ability to generate the same clonal tumor when serially
transplanted into immuno-compromised mice (Vermeulen et al., 2008). If cancer stem
cells are ultimately responsible for tumor maintainance then a theurapeutic strategy
capable of depleting the cancer stem cell pool may control malignancy. One potential
way to deplete a cancer stem cell population is to induce the differentiation of the stem
cells. As previously mentioned, differentiation is a process that requires increased
mitochondrial function and, for this reason, the role of MCL-1 inside the matrix may be
to facilitate differentiation. If matrix-localized MCL-1 promotes differentiation, then
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utilizing the MCL-1Matrix mutant as a strategy to induce differentiation and deplete the
cancer stem cell pool may be an alternative strategy to treat cancer.
BCL-2 Family Inhibitors
There has been an increasing interest in developing BCL-2 family inhibitors as a
cancer therapeutic strategy, focusing on antagonizing anti-apoptotic activity to foster cell
death (Oltersdorf et al., 2005). One such inhibitor, obatoclax, is a BH3-mimetic that
binds to BCL-2, BCL-XL, and MCL-1 to disrupt their interaction with the pro-apoptotic
molecules (Nguyen et al., 2007). Although obatoclax exhibits single-agent activity and
can kill certain types of cancer cells in-vitro, it also has non-specific effects in which nonapoptotic cell death occurs (Li et al., 2008; McCoy et al., 2010; Tse et al., 2008).
Additionally, ligands and modified peptides that are also BH3-mimetics modeled
specifically for MCL-1’s BH3-binding groove have been developed but to date appear to
be only effective when combined with chemotherapeutic agents (Lee et al., 2008; Stewart
et al., 2010b). One possibility for the lack of single-agent activity is that these BH3mimetics only antagonize MCL-1’s anti-apoptotic activity leaving its mitochondrial
function unaffected; thus, they may be insufficient to promote cell death unless combined
with another death-inducing agent. Paradoxically, genetic deletion of Mcl-1 induces cell
death in cancer cells regardless of complementary expression of other endogenous antiapoptotic family members (Glaser et al., 2012; Xiang et al., 2010). Only when other antiapoptotic BCL-2 family members are ectopically expressed can loss of MCL-1 be
tolerated in these cancer cells (Glaser et al., 2012; Xiang et al., 2010). Thus, it is possible
that the non-apoptotic, mitochondrial function of MCL-1 is important to promoting
cancer cell survival and proliferation, but that overexpression of pro-survival molecules
can overcome this stress. In light of the potential for MCL-1 to promote both cancer cell
apoptotic resistance and to support the high rate of proliferation often observed in cancer
cells, it is possible that inhibition of both the anti-apoptotic and mitochondrial functions
of MCL-1 may synergize by restricting cancer cell expansion and activating cell death,
thereby leading to more effective therapies.
Post-translational Regulation of MCL-1
Although MCL-1 has been shown to be ubiquitinated by several E3 ligases
including, MULE, ßTRCP and FBW7, it is difficult to observe both the 40 kD and 36 kD
isoforms of MCL-1 in these studies (Ding et al., 2007; Inuzuka et al., 2011; Zhong et al.,
2005). However, the different MCL-1 isoforms were shown to possess different protein
half-lives (De Biasio et al., 2007; Stewart et al., 2010a). For example, full length (40 kD)
MCL-1 has an extremely short half-life, approximately 2 hours, while the N-terminally
cleaved isoform (36 kD) is greater than 6 hours (Stewart et al., 2010a). This may be due
to the differential localization of these MCL-1 isoforms, since the turnover of outer
membrane and inner membrane proteins of the mitochondrion are quite different
(Brunner and Neupert, 1968). The average half-life of outer mitochondrial membrane
proteins was found to be ~4 days, which differs considerably from the half-life of inner
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membrane proteins, ~12 days (Brunner and Neupert, 1968). In addition to observing that
the MCL-1 isoforms have differential protein turnover rates, Stewart et al. also generated
a lysine-less MCL-1 mutant where 14 lysine residues were mutated to arginine (MCL1KR)(Stewart et al., 2010a). This mutant was unable to be ubiquitinated but, surprisingly
did not change the turnover rate of the 40 kD MCL-1 isoform, however, dramatically
changed the half-life of the 36 kD isoform from greater than 6 hours to ~2 hours (Stewart
et al., 2010a). These observations are unexpected because MCL-1KR was predicted to
increase MCL-1 half-life since it could not be marked for degradation by the proteasome.
A simple explanation for the rapid turnover of the 36 kD isoform of MCL-1KR is that this
mutant protein is not properly folding inside the mitochondria due to the 14 point
mutations which may cause aberrations in the protein secondary structure. Consequently,
the 36 kD isoform of MCL-1KR may be misfolded and degraded inside the mitochondrial
matrix by the AAA+ family of ATPases, such as Lon and ClpXP (Tatsuta and Langer,
2008). This hypothesis could simply be tested by RNA interference against Lon or
ClpXP proteases then monitoring MCL-1KR half-life. An alternative explanation is that
MCL-1 undergoes protein acetylation, which may facilitate the binding of another
adaptor protein that is important for MCL-1 protein stability inside the mitochondria.
MCL-1KR cannot be acetylated, due to the lack of lysine residues, and therefore
dissociates with its binding partner, destabilizing the 36 kD isoform. In order to test if
MCL-1 is acetylated, tandem mass spectroscopy can be used to identify potential MCL-1
acetylation sites. Validation of acetylation could be carried out by labeling cells with
[H3]
acetate, immunoprecipitating MCL-1 then analyzing via fluorography.
Despite observations that MCL-1 protein is rapidly degraded by the proteasome,
inhibition of the proteasome did not result in increased expression of the 40 kD isoform,
rather, it led to accumulation of the 38 kD isoform (De Biasio et al., 2007; Stewart et al.,
2010a). Indeed, findings from De Biaso et al. revealed that full length MCL-1 was
continually processed to the 36 kD isoform (De Biasio et al., 2007). Furthermore, the
processing of MCL-1 to the 36 kD form was shown to depend on a functional
mitochondrial membrane potential, suggesting that the cleavage occurs inside the
mitochondria (Warr et al., 2011). Along these lines, RNAi-mediated silencing of the
mitochondrial processing peptidase (MPP) ablated the formation of the 36 kD isoform of
MCL-1, indicating that MCL-1 processing takes place in the matrix (Huang and YangYen, 2010). In addition to proteasome-dependent degradation, proteolytic cleavage of
full-length MCL-1 may represent another mechanism for regulating its protein turnover.
It is possible that both inhibiting the proteasome and dissipating the mitochondrial
membrane potential may dramatically increase the half-life of full length MCL-1. To that
end, the MCL-1OM mutant could be predicted to have a longer half-life because it is
unable to be proteolytically cleaved, and therefore accumulates on the OMM.
Alternatively, MCL-1 OM could have a shorter half-life due to easier access by the
proteasome.
Differential regulation of MCL-1 isoforms resulting from a variety of cellular
stresses has also been documented. For example, DNA-damaging agents such as
etoposide and UV irradiation both increased the turnover rate of the 40 kD isoform with
no effect on the 36 kD form of MCL-1 (De Biasio et al., 2007; Stewart et al., 2010a).
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However, this may just be a reflection of the differential half lives of the two isoforms.
In contrast, nutrient-induced stress, such as cytokine or glucose withdrawal, appears to
reduce the levels of both isoforms of MCL-1 (Coloff et al., 2011; Maurer et al., 2006).
However, the nutrient deprivation appears to be regulating MCL-1 translation via mTOR
and could explain why there is less of both isoforms (Coloff et al., 2011; Pradelli et al.,
2010).
Regulation of Mitochondrial Function by MCL-1
My data suggests a new role of MCL-1 in regulating mitochondrial metabolism
and dynamics; a function separate from its ability to antagonize cell death that requires its
import into the mitochondrial matrix. During import, the MCL-1 protein undergoes
amino-terminal proteolytic cleavage resulting in the production of multiple proteins from
the same polypeptide. The generation of the matrix-localized MCL-1 requires two
proteolysis events and importation into the mitochondria by the translocases of the outer
and inner membrane (TOM and TIM complexes). It has also been shown that full-length
MCL-1 continually undergoes processing to the matrix-localized isoform that depends on
a functional mitochondrial membrane potential and may be processed by the MPP inside
the mitochondrial matrix (De Biasio et al., 2007; Huang and Yang-Yen, 2010; Warr et
al., 2011). Further studies will be required to identify whether cleavage at both sites
occurs within the mitochondria and/or whether other cellular proteases are involved.
Functionally, the OMM-localized MCL-1 possesses anti-apoptotic activity,
inhibiting cell death and binding pro-apoptotic molecules (Fig. 4.2). In contrast, the
matrix-localized MCL-1 does not possess anti-apoptotic function, but instead facilitates
normal mitochondrial physiology and energy metabolism. The matrix-localized MCL-1
promotes normal mitochondrial ultrastructure by maintaining cristae morphology as well
as the dynamics of mitochondrial fusion. Additionally, the MCL-1 matrix isoform
supports oxidative phosphorylation, ATP production and maintenance of mitochondrial
membrane potential. Thus, MCL-1 functions both to directly oppose apoptosis and to
promote mitochondrial physiology.
MCL-1 Modulates Inner Membrane Structure, Dynamics, and Function
While my data suggests that MCL-1 is required inside the mitochondrial matrix
for normal mitochondrial cristae structure, fusion, and bioenergetics, including oxidative
phosphorylation (OXPHOS), precisely how MCL-1 can promote this function is still
uncertain. Mitochondrial morphology, dynamics, and function are closely linked.
Particularly, the structure of the inner membrane is highly organized and dynamic. The
mitochondrial cristae are pleomorphic and adapt different structures according to the
metabolic status of the cell. For example, when ADP is low and ATP is abundant the
cristae are short and flat with fewer cristae junctions and an expanded matrix, called
“orthodox” (Hackenbrock, 1968). Whereas, under conditions of high ADP and low ATP,
the cristae have multiple tubular connections and a compact matrix, called “condensed”
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Figure 4.2. Classical Anti-apoptotic MCL-1
On the outer mitochondrial membrane (OMM), MCL-1 functions like other antiapoptotic
BCL-2 family members where it antagonizes the activation of BAX and BAK and
prevents cell death. MCL-1 can directly bind BH3-only family members, such as BIM,
sequestering them away from the pro-apoptotic effectors BAX or BAK. Alternatively,
MCL-1 may directly bind BAX and BAK and maintain them in an inactive conformation.
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(Hackenbrock, 1968). Since cells lacking MCL-1 inside the mitochondrial matrix have
profound deficits in bioenergetics, it is possible that MCL-1 may directly modulate the
function of one or more of the ETC components. In the absence of matrix-localized
MCL-1, the capacity for OXPHOS is diminished and ATP production plummets, thereby
indirectly affecting the cristae morphology and dynamics.
However, it is also possible that the dynamic transition between “orthodox” and
“condensed” requires an active fission and fusion process and MCL-1 could directly
modify this process. For example, MCL-1 could influence the function of OPA1, a wellcharacterized regulator of inner membrane fusion. In the absence of MCL-1 inside the
mitochondrial matrix, OPA1 activity may be perturbed resulting in fusion defects.
Furthermore, defects in mitochondrial fusion cause dysfunctional mitochondria. Cells
that are fusion incompetent generate less energy by OXPHOS and have increased ROS
production in addition to fragmented mitochondria (Chen et al., 2005a; Chen et al.,
2007). This is because fusion maintains a healthy mitochondrial population through the
exchange of contents between mitochondria including mtDNA. The mtDNA genome is
organized into nucleoids and encodes for essential components of the respiratory chain.
Fusion enables the exchange of mtDNA nucleoids between mitochondria, however, in
cells incapable of fusion there is a loss of nucleoids (Chen et al., 2007; Legros et al.,
2004). Consequently, a possible explanation for the decreased mtDNA content observed
in Mcl-1-deleted cells may be an effect of incompetent mitochondrial fusion;
subsequently, resulting in bioenergetic abnormalities such as inefficient respiration and
decreased membrane potential. Moreover, mitochondrial membrane potential influences
fusion efficiency (Song et al., 2007) and, therefore could cause a feed-forward inhibition
of fusion rate.
Alternatively, MCL-1 may regulate inner membrane structure by directly
facilitating the dimerization and oligomerizaton of F1F0-ATP synthase. ATP synthase
dimers and oligomers constrain and curve the IMM and this is required for maintaining
the proper organization of the IMM (Dudkina et al., 2005; Giraud et al., 2002; Thomas et
al., 2008). The assembly of ATP synthase into dimers and oligomers is aberrant in
mitochondria lacking MCL-1 (Fig. 4.3). It is possible that MCL-1 is an accessory protein
that bridges either the F1 or F0 domains, stabilizing the complex (Fig. 4.3). On the other
hand, MCL-1 could indirectly support dimerization through another accessory protein
such as inhibitory factor 1 (IF1). IF1 is a protein that binds to ATP synthase and prevents
the hydrolysis of ATP (Pullman and Monroy, 1963). IF1 regulates mitochondrial
ultrastructure by promoting dimerization of ATP synthase (Campanella et al., 2008).
Mcl-1-deleted mitochondria exhibit a loss of oligomeric ATP synthase and a
corresponding increase in monomeric form, indicating that those oligomers are less stable
in the absence of MCL-1. It is plausible that the loss of ATP synthase oligomers in Mcl1-deleted mitochondria may be responsible for the ultrastructural defects including
disorganized cristae. Similar defects were seen in the assembly of electron transport
chain (ETC) complexes into “supercomplexes” in MCL-1 deficient mouse liver
mitochondria (Fig. 4.3). It has been demonstrated that the assembly of the ETC
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Figure 4.3. MCL-1’s Potential Functions Inside Mitochondria
During mitochondrial importation, the full-length MCL-1 is proteolytically truncated on
its amino-terminus. The truncated, matrix localized MCL-1 resides within the inner
mitochondrial membrane where it functions to maintain mitochondrial cristae
ultrastructure and promotes the assembly of the electron transport chain complexes into
higher-order assemblies known as supercomplexes (SC). The assembly into
supercomplexes has been shown to facilitate electron transport efficiency and reduce the
production of deleterious reactive oxygen species. Additionally, matrix-localized MCL-1
facilitates the assembly of the higher-order assembly of the ATP synthase complexes into
dimers and oligomers. Proper assembly of oligomeric ATP synthase has been implicated
in being an important determinate of inner membrane cristae structure. Whether MCL-1
acts directly or indirectly to facilitate these macromolecular assemblies of the electron
transport supercomplexes or ATP synthase oligomers is still unclear.
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complexes into supercomplexes promotes efficient energy production and decreases the
production of harmful reactive oxygen species (Acin-Perez et al., 2008). Since
abnormalities in mitochondrial cristae ultrastructure can promote the breakdown of the
reticular mitochondrial network, this could explain the observed mitochondrial fusion
defect and subsequent bioenergetic abnormalities in Mcl-1-deficient cells (Velours et al.,
2009).
Another possible cause of the ultrastructural defects is an aberrant lipid inner
mitochondrial membrane. MCL-1 may directly or indirectly regulate the lipid content of
the inner mitochondrial membrane. For example, MCL-1 could facilitate the structure
and/or function of cardiolipin. Cardiolipin is an abundant lipid in the inner mitochondrial
membrane that affects mitochondrial ultrastructure and function (Houtkooper and Vaz,
2008). Furthermore, cardiolipin regulates supercomplex assembly of the repiratory
complexes and ATP synthase oligomerization (Wittig and Schagger, 2009). It is possible
that MCL-1 could indirectly affect cardiolipin structure. In the absence of MCL-1,
cardiolipin structure may be disrupted and this could alter the fusion of the lipids in the
inner mitochondrial membrane. Indeed, the lipid structure is very important for
membrane fusion (Cullis et al., 1986). Alternatively, MCL-1 could directly interact with
cardiolipin to facilitate its function, such that in the absence of this interaction a
functional change occurs, possibly even disrupting other cardiolipin complexes.
Concluding Remarks
My findings regarding MCL-1-regulated mitochondrial physiology and its
separable functions as an anti-apoptotic molecule at the OMM and regulator of
mitochondrial bioenergetics inside the matrix, may have a major impact in our
understanding of MCL-1 biology in normal cells, and represent a new clinical target.
Recently, another anti-apoptotic BCL-2 family member, BCL-XL, was found inside the
mitochondrial matrix where it also played a role in mitochondrial metabolism (Alavian et
al., 2011). While BCL-XL was found to regulate mitochondrial metabolism, there was no
indication that it played a role in mitochondrial morphology (Alavian et al., 2011). For
this reason, BCL-XL may be able to functionally compensate for the metabolic role of
MCL-1 inside the mitochondrial matrix. Additionally, if BCL-XL was also able to
compensate for the morphology abnormalities observed in Mcl-1-deficient cells, this
would suggest that the regulation of mitochondrial metabolism is MCL-1’s primary role
inside the mitochondria. Undoubtedly, defining the mechanism by which MCL-1
regulates mitochondrial physiology as well as identifying MCL-1-interacting partners
inside the mitochondrial matrix will be important to understanding its function. Future
studies delineating the relative contributions of MCL-1’s anti-apoptotic and metabolic
functions in both normal and diseased cells may help to develop more effective MCL-1
inhibitors with reduced toxicity to normal cells.
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